How to read a tag. Only
verified counts toward a score — it means a typed connector
resolved this against a primary US federal record.
unconfirmed means the Verifier checked and could not confirm,
which very often means the source could not be queried at all rather than that
the claim is doubtful. refuted means a primary source
contradicts it. unverified means nothing has checked it yet.
21 CFR (Title 21 of the Code of Federal Regulations) 870.5800 classifies a "compressible limb sleeve" — a device used to prevent pooling of blood in a limb by periodically inflating a sleeve around the limb — as Class II (FDA device class II), with FDA (US Food and Drug Administration) product code JOW, and multiple intermittent pneumatic compression systems have been cleared under that regulation and product code via 510(k) (premarket notification).
jurisdiction: US — confidence: verified — note: all three components confirmed independently. eCFR returns the full section verbatim: "A compressible limb sleeve is a device that is used to prevent pooling of blood in a limb by inflating periodically a sleeve around the limb. (b) Classification. Class II (performance…the full check standards)." openFDA returns class 2, "Sleeve, Limb, Compressible", regulation 870.5800, review panel CV for product code JOW. Cleared devices exist: K012979 (an FDA 510(k) clearance number) ("COMPRESSIBLE LIMB SLEEVE", decided 2002-05-08), and the two K-numbers the Generator named both resolve to real IPC clearances whose Indications for Use are DVT prophylaxis and venous/edema indications — K160180 "to prevent DVT ... Circulation Enhancement, Deep Vein Thrombosis Prophylaxis, Edema ... Venous Stasis / Venous Insufficiency"; K140813 "intended to be used with an intermittent pneumatic device to increase venous blood flow in at risk patients in order to help prevent deep vein thrombosis and pulmonary embolism". Not one of those IFUs mentions orthostatic hypotension or the abdomen, which is the point claim 2verified makes. — source: regulation 870.5800 --title 21 --jurisdiction US --expect "limb" → verified, eCFR versioner title-21, issue 2026-09-16, section=870.5800; classification --product-code JOW --jurisdiction US → verified, openFDA device/classification product_code=JOW; 510k "compressible limb sleeve" --jurisdiction US → verified, openFDA device/510k k_number=K012979; clearance-summary K160180 → verified, FDA 510(k) summary K160180 (https://www.accessdata.fda.gov/cdrh_docs/pdf16/K160180.pdf); clearance-summary K140813 → verified, FDA 510(k) summary K140813 (https://www.accessdata.fda.gov/cdrh_docs/pdf14/K140813.pdf).
The text of 21 CFR 870.5800 describes compression of a limb and prevention of blood pooling in a limb; it does not by its terms describe compression of the abdomen or splanchnic vascular bed, and it does not by its terms describe treatment of orthostatic hypotension. Whether FDA would find an abdominal, posture-triggered device carrying an orthostatic-hypotension treatment claim substantially equivalent to a device under this regulation is an open substantial-equivalence question that the regulation text alone does not settle.
jurisdiction: US — confidence: verified — note: tag covers the text half only, and the recorded lookups read unconfirmed because this claim asserts an absence — the connector reports a phrase miss as unconfirmed by design, and here the miss is the finding. The section is three sentences long and eCFR returned all…the full check of it: it contains "limb" three times and contains neither "abdomen" nor "orthostatic". The second sentence of the claim asserts only that the substantial-equivalence question is open, which no connector in this repo can resolve in either direction — the eCFR connector serves regulation text, not FDA guidance, enforcement practice, or SE judgments. A Q-Sub is the only instrument that settles it, and it is human-run. — source: regulation 870.5800 --title 21 --jurisdiction US --expect "abdomen" → unconfirmed: "exists but its text does NOT contain the phrase 'abdomen'", eCFR versioner title-21, issue 2026-09-16, section=870.5800; regulation 870.5800 --title 21 --jurisdiction US --expect "orthostatic" → unconfirmed: "exists but its text does NOT contain the phrase 'orthostatic'", same section.
No FDA 510(k) clearance and no De Novo (De Novo classification request) grant for a device indicated to treat orthostatic hypotension (neurogenic or otherwise) by automated, posture-triggered abdominal or splanchnic compression was identified by the Generator's web search.
jurisdiction: US — confidence: unconfirmed — note: the 510(k) half was searched and returned nothing that contradicts the claim — but a null openFDA device-name search is unconfirmed, never proof of absence, and it searches device names, not indications, so a differently-named cleared device carrying an OH (orthostatic hypotension)…the full check indication would not surface. One near hit: K823663 "ABDOMINAL BINDER / Warm & Form, Orthopedic Materials", decided 1982-12-30 — a general support garment, not a powered or OH-indicated device. Verifier re-run 2026-09-29 (checked against the frontmatter intended_use: prescription home use, servo-controlled abdominal compression on assumption of upright posture, symptomatic nOH in primary autonomic failure): the De Novo half is now checked and is consistent with the claim, but not proven. data/fda_denovo.csv is present (494 records, decision dates 1998 to 2026, fetched to 09/24/2026 by fetch_denovo.py, which refuses to write a partial file). Six device-name queries ("abdominal compression", "orthostatic hypotension", "splanchnic compression", "abdominal binder", "orthostatic", "compression") each returned connector status refuted, meaning "no granted De Novo matching this name". Polarity warning for Factor 1: the connector's refuted refutes the existence of a matching De Novo grant, which is what this claim asserts. It is not a refutation of the claim and must not be tagged as one. The claim is still not verified: the listing is keyed on device names, not indications, so a differently-named De Novo device carrying an OH indication would not surface. The nearest OH-adjacent names in the file are DEN160044 (an FDA De Novo decision number) (Acumen Hypotension Prediction Index, a monitoring algorithm) and DEN230076 (Omron BP monitor), and neither is a compression therapy. The 510(k) half is unchanged: null name searches, not proof of absence. Tag stays unconfirmed. — source: 510k "orthostatic hypotension" --jurisdiction US → unconfirmed: "No 510(k) record found"; 510k "abdominal compression" --jurisdiction US → unconfirmed: "No 510(k) record found"; 510k "splanchnic compression" --jurisdiction US → unconfirmed: "No 510(k) record found"; 510k "abdominal binder" --jurisdiction US → verified, openFDA device/510k k_number=K823663 (1982 general binder, no OH claim); denovo "abdominal compression" --jurisdiction US → unconfirmed: "No local cache at data/fda_denovo.csv ... Do not substitute a web search for this file." (superseded); Verifier 2026-09-29: denovo "<name>" --jurisdiction US for each of the six names above → refuted (no match), source_ref "local cache of FDA De Novo listing (no match), device_name='<name>'", detail "No granted De Novo request matching '<name>' in the cached FDA De Novo listing (494 records)... refutes the De Novo route specifically, not market authorization generally."; re-run 2026-09-29 for the queue, explicit form: denovo "abdominal compression" --jurisdiction US → refuted, local cache of FDA De Novo listing (no match), device_name='abdominal compression'. Tag holds at unconfirmed: the claim asserts no grant was identified, so a name miss agrees with it, and a name miss cannot prove an absence of a differently-named grant.
Devices marketed as elastic or hook-and-loop abdominal binders are widely sold in the US as general support garments without an orthostatic-hypotension treatment claim, and abdominal binders are described in published consensus guidance on the management of neurogenic orthostatic hypotension as a non-pharmacologic measure.
jurisdiction: US — confidence: unconfirmed — note: unchanged and unresolvable as written. The guidance half names no PMID (PubMed identifier), guideline title or document identifier, so literature-detail has nothing to run against and I did not go hunting for a document the Generator never identified — that would be me sourcing the…the full check claim rather than checking it. The "widely sold" half is weakly and partially touched by K823663 (a 510(k)-cleared ABDOMINAL BINDER with no OH claim, recorded under claim 3unconfirmed), which is one device and not a market-breadth finding. Needs a specific guideline identifier appended as a new claim before it can move. — source: no runnable invocation — claim carries no resolvable identifier; related lookup recorded at claim 3unconfirmed.
PMID 27271310 (Okamoto LE, Diedrich A, Baudenbacher FJ, et al., "Efficacy of Servo-Controlled Splanchnic Venous Compression in the Treatment of Orthostatic Hypotension: A Randomized Comparison With Midodrine," Hypertension 2016;68(2):418-426) reports an automated inflatable abdominal binder delivering sustained servo-controlled venous compression at 40 mmHg (millimetres of mercury), activated only on standing, tested in 19 patients with autonomic failure in a single-blind crossover design against placebo and against midodrine, with orthostatic symptom burden decreasing with the binder and with midodrine but not with placebo.
jurisdiction: US — confidence: verified — note: the PubMed record was retrieved and every asserted element is in the abstract verbatim — "automated inflatable abdominal binder that provides sustained servo-controlled venous compression (40 mm Hg) and can be activated only on standing", "19 autonomic failure patients",…the full check "single- blind, crossover study", symptom burden 21.9±3.6 → 16.3±3.1 (P=0.032) with binder, 25.6±3.4 → 14.2±3.3 (P<0.001) with midodrine, 19.6±3.5 → 20.1±3.3 (P=0.756) with placebo. What is verified is what the paper reports; the abstract is unappraised (no methods detail, no risk-of-bias, no funding disclosure) and the record carries its own registration, NCT00223691 (a ClinicalTrials.gov registration number) — a different NCT from claims 6 and 7. — source: literature-detail 27271310 → found, PubMed PMID=27271310 (efetch), https://pubmed.ncbi.nlm.nih.gov/27271310/.
ClinicalTrials.gov registration NCT03482297 ("Automated Abdominal Binder for Orthostatic Hypotension") describes a randomized, double-blind, sham-controlled study at Vanderbilt comparing an automated abdominal binder inflated to 40 mmHg against a sham binder inflated to 5 mmHg, and against midodrine, in patients with primary autonomic failure disabled by orthostatic hypotension.
jurisdiction: US — confidence: verified — note: registry record retrieved: INTERVENTIONAL, PHASE1/PHASE2, RANDOMIZED, PARALLEL, masking=DOUBLE, sponsor Vanderbilt University Medical Center (PI Luis E Okamoto, NHLBI collaborator), enrollment 28 ACTUAL, population MSA (multiple system atrophy) and Pure Autonomic Failure with neurogenic OH and…the full check OHSA composite ≥4, status COMPLETED. The registry's own design description reads "Randomized, double-blind, sham-controlled, parallel-group ... in patients with primary autonomic failure disabled by neurogenic orthostatic hypotension"; the active arm inflates "(~40 mmHg) every time the participant stands up", the sham arm "(~5 mmHg)", and both arms include a 10 mg t.i.d. midodrine study day. hasResults=false — no results are posted, so this verifies a study design, not an outcome, and nothing in Factor 6 may lean on it as a finding. — source: trial-detail NCT03482297 → found, ClinicalTrials.gov NCTId=NCT03482297, https://clinicaltrials.gov/study/NCT03482297 (arm and masking detail read from that same registry record via its API).
ClinicalTrials.gov registration NCT01971008 ("Abdominal Binder to Treat Orthostatic Hypotension (OH) in Parkinson's Disease (PD (Parkinson disease))") exists as a separate registered study of abdominal binding for orthostatic hypotension in Parkinson disease.
jurisdiction: US — confidence: verified — note: record retrieved under that exact title; it is a distinct study from NCT03482297. Three things the claim did not know and a reader should: the sponsor is Medical University Innsbruck, so despite the US-registry jurisdiction tag this is Austrian clinical activity, not…the full check US; the intervention is an elastic binder versus a placebo binder, not a powered or servo-controlled one, so it is a weaker mechanism precedent than claim 5verified; and it is PHASE2, RANDOMIZED, CROSSOVER, masking=SINGLE, enrollment 15 ACTUAL, COMPLETED, with hasResults=true (posted results exist and were not read here). Primary outcome is change in mean BP after 3 minutes of passive orthostatic challenge. — source: trial-detail NCT01971008 → found, ClinicalTrials.gov NCTId=NCT01971008, https://clinicaltrials.gov/study/NCT01971008.
No device of this candidate's design exists as a prototype, and no bench, animal, or human data exist for it specifically; every performance property attributed to it in this file is design intent.
jurisdiction: US — confidence: unconfirmed — note: no connector in this repo can confirm or deny the state of an unbuilt concept — there is no database of things that do not exist. Recorded as the Generator's own disclosure, which is the right place for it; it stays out of every score either way. — source: no runnable…the full check invocation — self-report about an unbuilt device, structurally outside every connector.
A Medicare national coverage determination for pneumatic compression devices exists (commonly cited as NCD 280.6 (a Medicare national coverage determination number)) whose covered indications are lymphedema and chronic venous insufficiency with venous stasis ulcers; it does not establish national coverage of pneumatic compression for orthostatic hypotension.
jurisdiction: US — confidence: verified — note: the NCD (national coverage determination) manual text was read directly, not inferred from a code index. NCD 280.6 "Pneumatic Compression Devices" states the device "consist[s] of an inflatable garment for the arm or leg" and that "Pneumatic devices are covered for the treatment of lymphedema or for the…the full check treatment of chronic venous insufficiency with venous stasis ulcers." Orthostatic hypotension appears nowhere in the policy. Two further constraints the claim did not carry, both adverse to this candidate's base case: coverage is conditioned on a documented four-week conservative-therapy trial for lymphedema and a six-month one for CVI ulcers, and the garment described is a limb garment. This is a reimbursement obstacle, confirmed as one. Caveat from the connector: this is existence and text only, not a determination that any particular device is payable. — source: ncd 280.6 --jurisdiction US → verified, CMS (Centers for Medicare & Medicaid Services) Pub. 100-3 Medicare NCD Manual, chapter 1 part 4 (Rev. 13808, issued 05-29-26), section=280.6.
HCPCS (Healthcare Common Procedure Coding System) Level II codes E0650 (a HCPCS code for durable medical equipment), E0651 and E0652 exist for pneumatic compressors, and the code family includes appliance codes for trunk and chest application (the Generator believes E0656 and E0657, not confirmed). No HCPCS code specific to a powered, posture-triggered abdominal compression device indicated for orthostatic hypotension was identified.
jurisdiction: US — confidence: unconfirmed — note: Verifier re-run 2026-09-29 against data/hcpcs_level_ii.csv (CMS October 2026 alpha-numeric HCPCS file, member HCPC2026_OCT_ANWEB_09232026.txt). The code-existence half is verified, including the part the Generator flagged as unconfirmed. E0650 "Pneumatic…the full check compressor, non-segmental home model", E0651 "Pneumatic compressor, segmental home model without calibrated gradient pressure", E0652 "Pneumatic compressor, segmental home model with calibrated gradient pressure", E0656 "Segmental pneumatic appliance for use with pneumatic compressor, trunk" and E0657 "Segmental pneumatic appliance for use with pneumatic compressor, chest" all return verified, and none carries a termination date in the file. The no-specific-code half stays unconfirmed.hcpcs is keyed on the code, not the description, so no connector can check that no code in the set fits a posture-triggered abdominal nOH device. This half is about codes only: whether any code pays, or is covered, for this device was not checked here (see claims 9 and 40). The earlier NCD 280.6 inference is superseded by these direct lookups. Tag stays unconfirmed because of the negative half only. — source: hcpcs E0650 → unconfirmed: "No local cache at data/hcpcs_level_ii.csv ... Do not substitute a web search for this file." (E0651, E0652, E0656, E0657 not separately attempted — same missing file) (superseded); Verifier 2026-09-29: hcpcs E0650|E0651|E0652 --expect "Pneumatic compressor" --jurisdiction US → verified, hcpcs E0656 --expect "trunk" --jurisdiction US → verified, hcpcs E0657 --expect "chest" --jurisdiction US → verified; source_ref "local cache of CMS HCPCS Level II file, code=<code>".
Midodrine and droxidopa are FDA-approved prescription drugs for symptomatic orthostatic hypotension (droxidopa's approval being specific to symptomatic neurogenic orthostatic hypotension in primary autonomic failure and related conditions), both dispensed as outpatient pharmacy benefit rather than under the Part B device benefit, and both carry labeled supine-hypertension risk.
jurisdiction: US — confidence: unconfirmed — note: unconfirmed for a tooling reason. This repo has no drug connector at all — no Drugs@FDA, no DailyMed, no label reader — so no approval status, indication wording, or boxed-warning text can be checked here, and I did not substitute a web search. The nearest…the full check independent corroboration on record is incidental: the NCT03482297 registry record (claim 6verified) uses "10 mg midodrine t.i.d" as the standard of care comparator arm, which is consistent with midodrine being an approved therapy in this indication but is not a label check. Needs a human-attached Drugs@FDA label or a new connector. — source: no runnable invocation — no drug-label connector exists in this repo; corroborating context at claim 6verified.
Federal Register document 2026-16368 (91 FR 51710) states that eligibility for the coverage pathway it describes is limited to Class II and Class III (FDA device class III) FDA Breakthrough-designated devices, and that entry occurs at the IDE presubmission stage.
jurisdiction: US — confidence: verified — note: both phrases read out of the document's own full text. The document is "Medicare Program; Regulatory Alignment for Predictable and Immediate Device (RAPID) Coverage Pathway", a Notice published 2026-08-11 by CMS. On eligibility: "The RAPID coverage pathway will provide…the full check accelerated Medicare beneficiary access to certain eligible Class II and Class III U.S. Food and Drug Administration (FDA) Breakthrough-designated Devices." On entry stage: "The device must also be at the IDE presubmission stage and be the subject of an IDE study that enrolls Medicare beneficiaries and studies clinical health outcomes that FDA and CMS have agreed are appropriate". One qualifier the claim does not carry and a reader of the upside case should: the surrounding sentence conditions on "designated Breakthrough Devices planning to submit a PMA (premarket approval) application", with 510(k) devices admitted only via the narrow footnote at claim 19verified. — source: policy 2026-16368 --expect "Class II and Class III" → verified, Federal Register document_number=2026-16368 (91 FR 51710); policy 2026-16368 --expect "presubmission" → verified, same document.
Federal Register document 2026-16368 (91 FR 51710) states that eligibility for that pathway requires the device to be separately payable — billable to Medicare in its own right.
jurisdiction: US — confidence: verified — note: the phrase appears in the eligibility list itself: "Not already the subject of a controlling Medicare NCD; Separately payable devices that can, if approved, be billed to Medicare; and Not otherwise excluded from coverage through law or regulation." Note the adjacent…the full check criterion, which the candidate does not discuss: a device "already the subject of a controlling Medicare NCD" is excluded, and NCD 280.6 (claim 9verified) is a controlling NCD over pneumatic compression devices — whether it would be read as controlling over this device is a CMS judgment no connector settles, but it is a question the upside case has to answer. Whether this device is separately payable remains claim 32unconfirmed, an assumption. — source: policy 2026-16368 --expect "separately payable" → verified, Federal Register document_number=2026-16368 (91 FR 51710).
Federal Register document 2026-16368 (91 FR 51710) states that IVD (in vitro diagnostic) products will not be accepted into that pathway, with coverage for Breakthrough-designated IVDs left to Medicare Administrative Contractors. This candidate, on its stated intended use, is a therapeutic device and not an IVD.
jurisdiction: US — confidence: verified — note: verbatim in the document: "...coverage determinations for IVDs which have been granted Breakthrough Device designation should continue to be determined by the MACs through existing pathways. Therefore, IVD products will not be accepted into the RAPID coverage pathway."…the full check The second sentence of the claim is a self-description of this file's own intended_use: (home-use servo-controlled abdominal compression to reduce orthostatic symptom burden — a treatment claim, not a diagnostic one) and is not a connector-checkable fact; the tag rests on the first sentence. — source: policy 2026-16368 --expect "IVD products will not be accepted" → verified, Federal Register document_number=2026-16368 (91 FR 51710).
Federal Register document 2026-16368 (91 FR 51710) is a notice with comment period, not a final rule; its comment period closes 2026-10-13, and nothing in it was in force on the date this candidate was generated.
jurisdiction: US — confidence: verified — note: the document type check is the one check in this family that returns refuted on a mismatch, and it passed: the Federal Register records this as a Notice, published 2026-08-11, with no effective date recorded and comment period closing 2026-10-13. Every…the full check element of the claim holds, including the third — with the comment period still open on today's date (2026-09-18), this instrument states what CMS intends, not a settled requirement. Any Factor 2 or Factor 7 arithmetic that assumes RAPID is operating is assuming a fact not in evidence. — source: policy 2026-16368 --expect-type notice → verified, Federal Register document_number=2026-16368 (91 FR 51710).
Federal Register document 2026-16368 (91 FR 51710) states that the Transitional Coverage for Emerging Technologies (TCET) pathway is paused for new candidates upon that notice's publication.
jurisdiction: US — confidence: verified — note: verbatim: "The TCET pathway will be paused for new candidates upon publication of this notice with comment period as CMS focuses on the successful implementation of the RAPID coverage pathway." Consequence worth stating plainly: as of 2026-09-18 the older pathway is…the full check paused and the newer one is a notice under comment (claim 15verified), so neither is an available route today. — source: policy 2026-16368 --expect "paused" → verified, Federal Register document_number=2026-16368 (91 FR 51710).
Federal Register document 2024-17603 (89 FR 65724) established the TCET pathway by final procedural notice and states that CMS did not anticipate being able to accept more than five candidates into that pathway per year based on then-current resources.
jurisdiction: US — confidence: verified — note: document confirmed as "Medicare Program; Transitional Coverage for Emerging Technologies", a Notice published and effective 2024-08-12 — which matches "final procedural notice" rather than a rule. The capacity statement is verbatim: "Based on current resources, we do…the full check not anticipate being able to accept more than five candidates into the TCET pathway per year. As we gain more experience with TCET, we will re-evaluate and adjust if we can do so within our available resources." — source: policy 2024-17603 --expect "more than five candidates" → verified, Federal Register document_number=2024-17603 (89 FR 65724); policy 2024-17603 → verified (Notice, published 2024-08-12, effective 2024-08-12).
Federal Register document 2021-24916 (86 FR 62944) is a final rule repealing the Medicare Coverage of Innovative Technology and Definition of "Reasonable and Necessary" final rule, which had been published 2021-01-14 as Federal Register document 2021-00707 (86 FR 2987) and was to have been effective 2021-12-15; the repeal took effect before the original rule ever operated.
jurisdiction: US — confidence: verified — note: every element holds, including the one that looked shakiest. 2021-24916 is recorded as a Rule published 2021-11-15, effective 2021-12-15, and its own text reads: "This final rule repeals the ``Medicare Coverage of Innovative Technology (MCIT) and Definition of…the full check `Reasonable and Necessary'' final rule, which was published on January 14, 2021, and was to be effective on December 15, 2021. DATES: This final rule is effective December 15, 2021." 2021-00707 exists as claimed (86 FR 2987, Rule, published 2021-01-14). One discrepancy that is not a contradiction: the FR metadata for 2021-00707 carries effective date **2021-03-15**, its original date, which was subsequently delayed to 2021-12-15 — the delay documents were not retrieved, but the repeal rule itself states the 2021-12-15 date the claim asserts. Repeal effective the same day MCIT would first have operated: the claim's characterisation stands. — source: policy 2021-24916 --expect "repeal" → verified, Federal Register document_number=2021-24916 (86 FR 62944); policy 2021-24916 --expect "December 15, 2021" → verified, same document; policy 2021-00707` → verified, Federal Register document_number=2021-00707 (86 FR 2987, Rule, published 2021-01-14, effective 2021-03-15).
Federal Register document 2026-16368 (91 FR 51710) contains a provision admitting 510(k) devices to that pathway where the primary predicate was De Novo-authorized within 18 months of acceptance.
jurisdiction: US — confidence: verified — note: the Generator flagged that it had not read this provision and asked to be refuted if it was not there. It is there, verbatim, as footnote 18: "Includes 510(k) cleared devices where the primary predicate was authorized via the De Novo classification pathway no earlier…the full check than 18 months prior to acceptance into the RAPID coverage pathway." Read against this candidate: the footnote is an exception to a PMA-oriented eligibility rule (claim 12verified), and it requires a recent De Novo predicate, which claim 3unconfirmed records as not identified — so on the second device_class route (510(k) to JOW, a 1980s-era limb regulation) this provision would not reach the device. It reaches a device only on a narrow path: some other party's De Novo grant in this space within the preceding 18 months. — source: policy 2026-16368 --expect "18 months" → verified, Federal Register document_number=2026-16368 (91 FR 51710); policy 2026-16368 --expect "primary predicate" → verified, same document; policy 2026-16368 --expect "510(k)" → verified, same document.
Public Law 114-255 section 3051 added section 515B to the Federal Food, Drug, and Cosmetic Act (codified at 21 U.S.C. 360e-3), establishing the Breakthrough Devices Program, under which a device may qualify where it provides for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions and either represents a breakthrough technology, has no approved or cleared alternatives, offers significant advantages over existing approved or cleared alternatives, or where availability is otherwise in the best interest of patients.
jurisdiction: US — confidence: unconfirmed — note: unconfirmed for a tooling reason. This is a statutory claim, and no connector in this repo reads the US Code, the Statutes at Large, or a Public Law. regulation serves the eCFR only — 21 U.S.C. 360e-3 is not a CFR section, and running it against the eCFR would…the full check have produced a meaningless refuted about a section number that was never in the CFR, so I did not. I also did not substitute a web search. Separately and independently: no connector here reads FDA Breakthrough designation status for any device, so the candidate's eligibility under the "no approved or cleared alternatives" limb — the limb the narrowed indication is scoped against — is unreachable from this repo in both directions. — source: no runnable invocation — statute text is outside every connector's scope (eCFR connector serves 21 CFR, not 21 U.S.C.).
TAM (total addressable market) component 1 of 4 — population base: approximately one million people in the United States are living with Parkinson disease and approximately 90,000 are newly diagnosed each year.
jurisdiction: US — confidence: unconfirmed — note: permanently unconfirmed absent a human-attached source. The market connector returns unverifiable by design and no agent may upgrade it. The substitute the Generator itself named — CMS Chronic Conditions Data Warehouse Parkinson prevalence among Medicare FFS (fee-for-service)…the full check beneficiaries — has no connector in this repo either, so it is a human fetch, not an agent one. Note that the CCW figure would in any case be a Medicare-FFS floor, not a US prevalence figure: it excludes Medicare Advantage (Medicare Advantage), commercial, Medicaid, VA and cash-pay, and excludes under-65 PD entirely. — source: market "approximately one million people in the US live with Parkinson disease and ~90,000 newly diagnosed each year" → unverifiable: "no free, authoritative, machine-queryable source ... Stays unconfirmed permanently unless a human attaches a licensed report".
TAM component 2 of 4 — clinical fraction: a systematic review and meta-analysis of 55 studies comprising 10,463 patients with Parkinson disease (PMID 41767005) reports pooled prevalence of orthostatic hypotension of 33% (95% CI 28-37%), with the neurogenic subtype at 26%, and with symptomatic and asymptomatic orthostatic hypotension at approximately 20% and 22% respectively.
jurisdiction: US — confidence: verified — note: record retrieved and every figure matches the abstract exactly — "55 studies involving 10,463 patients", "combined prevalence of orthostatic hypotension (OH) was 33% (95%CI, 28-37%)", "combined prevalence of neurogenic orthostatic hypotension was 26%", "symptomatic and…the full check asymptomatic ... (20 and 22%, respectively)", and the regional figure the claim's own note flags, "North America (28%)". Three things the claim omits and a market model must not: heterogeneity is I²=96%, which the authors themselves call a constraint on the pooled number; publication-bias adjustment by trim-and-fill drops the estimate to 24.9%; and the claim's US jurisdiction tag sits over a non-US-restricted evidence base (Europe 42%, Asia 32%). Use 24.9-28%, not 33%, for a US-scoped model. — source: literature-detail 41767005 → found, PubMed PMID=41767005 (efetch), https://pubmed.ncbi.nlm.nih.gov/41767005/.
TAM component 3 of 4 — price per unit: the Generator assumes a device selling price and a Medicare allowable in the range of existing DMEPOS (durable medical equipment, prosthetics, orthotics and supplies) pneumatic-compressor purchase allowables under HCPCS E0650-E0652, and asserts no specific figure. No payment rate was extracted from any CMS fee schedule.
jurisdiction: US — confidence: unconfirmed — note: unconfirmed twice over, for two different reasons that should not be conflated. The assumption half is a market claim and returns unverifiable by design. The checkable half — the published DMEPOS allowable for E0650/E0651/E0652 — is **unconfirmed for a tooling…the full check reason**: payment needs data/hcpcs_payment_rates.csv and that file is absent here, so no rate was looked up in either direction. This is the component most likely to move once the cache lands, and until it does there is no dollar figure anywhere in this TAM. — source: payment E0650 → unconfirmed: "No local cache at data/hcpcs_payment_rates.csv ... Do not substitute a web search for this file."; market "device selling price and Medicare allowable in the range of existing DMEPOS pneumatic-compressor purchase allowables under HCPCS E0650-E0652" → unverifiable; Verifier 2026-09-29 re-check, tag holds at unconfirmed: payment E0650 --jurisdiction US → verified, local cache of CMS DMEPOS fee schedule, code=E0650, modifier=NU+RR+UE, schedule=DMEPOS, release=July 2026; payment E0651 --jurisdiction US → verified (same, E0651); payment E0652 --jurisdiction US → verified (same, E0652). The published purchase (NU) allowables now exist on record — E0650 $872.43-$1,026.39, E0651 $1,112.52-$1,308.85, E0652 $6,422.01-$7,555.31 non-rural across contiguous states/DC (allowed amounts, not payment) — but the claim is the Generator's assumption that this device prices in that range, which the fee schedule cannot confirm. Note also all three are category IN, not capped rental (claim 117refuted).
TAM component 4 of 4 — addressable share: the Generator assumes that the addressable population is the subset of patients with symptomatic neurogenic orthostatic hypotension who remain symptomatic on non-pharmacologic measures, who have sufficient manual dexterity or caregiver support to don and operate a powered abdominal garment daily, and whose prescribers would choose a device over or alongside a pressor drug. No share figure is asserted and no primary research supports any share figure.
jurisdiction: US — confidence: unconfirmed — note: permanently unconfirmed. Two of the three filters in this share are stakeholder-behaviour assertions (claims 28 and 29 restate them), which no database answers and which I will not answer from my own judgment — a model's estimate of what patients and prescribers would…the full check do is a fabricated claim, not a weak one. Needs interviews, a survey, or a published preference study, human-attached. — source: market "addressable share is the subset of symptomatic nOH patients who remain symptomatic on non-pharmacologic measures and can operate a powered abdominal garment" → unverifiable: "no free, authoritative, machine-queryable source".
TAM volume anchor: annual Medicare fee-for-service utilization of HCPCS E0650, E0651 and E0652 is published in CMS DMEPOS utilization data and is the checkable volume floor for a device priced into that channel; the Generator extracted no figure and asserts none.
jurisdiction: US — confidence: verified — note: Verifier 2026-09-29 re-check: the DMEPOS release is now cached (data/medicare_dme_volumes.csv, CMS "Medicare DMEPOS by Referring Provider Geography and Service", data.cms.gov 2026-07 release, retrieved 2026-09-29) and publishes national FFS utilization for all three…the full check codes, which is what the claim asserts; it asserts no figure, so nothing else is being tested. Figures read, by beneficiaries (the patient/device count) with services beside them: E0650 purchase 97 beneficiaries / 97 services, rental 52 beneficiaries / 105 services (rental months); E0651 purchase 34,399 / 34,403, rental 105 / 512; E0652 purchase 6,792 / 6,792, rental 160 / 924. Beneficiaries are not summable across lines. The file does not state the service year (see data/provenance.json). Medicare FFS floor only: excludes Medicare Advantage, commercial, Medicaid, VA and cash-pay; never a market size, and these are lymphedema/venous compressor volumes, not nOH patients. Earlier note (2026-09-18, superseded): unconfirmed for a tooling reason, and this is the one TAM component a US primary source could actually settle. All three codes are supplier-billed DMEPOS codes, and the cached release (data/medicare_procedure_volumes.csv) covers physician-billed services and carries essentially no E-prefixed codes — the connector's own words, "Nothing was looked up in either direction. This is a missing-file gap, not evidence that the code has no volume, and it must not be read as one." The release that answers it is CMS "Medicare Durable Medical Equipment, Devices & Supplies — by Geography and Service" (data.cms.gov), uncached and not yet readable by this connector (docs/backlog.md 1.13). When it lands, note that any figure it gives is a Medicare-FFS floor on US volume — excluding Medicare Advantage, commercial, Medicaid, VA and cash-pay — and never a market size. — source: procedures E0650 --jurisdiction US → unconfirmed (DMEPOS gap, see detail above); procedures E0651 --jurisdiction US → unconfirmed (same); procedures E0652 --jurisdiction US → unconfirmed (same) (all three superseded); Verifier 2026-09-29: procedures E0650 --jurisdiction US → verified, local cache of CMS Medicare DMEPOS utilization file (referring provider geography and service), code=E0650, geography=National; procedures E0651 --jurisdiction US → verified (same, code=E0651); procedures E0652 --jurisdiction US → verified (same, code=E0652).
FTO (freedom to operate) — named family: US patent application publication US20150313608A1, filed on or about 2015-04-30 and naming inventors associated with Vanderbilt University (Okamoto, Diedrich, Baudenbacher, Harder, Biaggioni), covers an automated inflatable abdominal binder for countering the effects of orthostatic hypotension, and is listed by Vanderbilt's technology transfer office as an available technology. The Generator did not determine whether this application issued as a granted patent, what its granted claims cover if so, who the current assignee or exclusive licensee is, or its expiry date. This is a named, potentially blocking family directly on this candidate's mechanism.
jurisdiction: US — confidence: verified — note: the family is real and it is on-mechanism — this is the most consequential finding of this pass. EPO (European Patent Office) OPS returns the document under epodoc US2015313608: title "Compression device, system, and method for decreasing abdominal venous pooling", filed 2013-11-04,…the full check naive 20-year term expiration 2033-11-04, not expired. Read the tag narrowly. Three components are confirmed — the document exists, its subject matter is abdominal venous-pooling compression, and it is live on a naive term basis. Three are not: (a) the claim's filing date of "on or about 2015-04-30" is not what the record says — EPO gives 2013-11-04, which is either the priority filing or a different family member, and the discrepancy should be resolved before anyone cites a date; (b) inventor names, current assignee, and the Vanderbilt CTTC availability listing were not returned by the connector and remain unchecked; (c) grant status and claim scope remain undetermined — this is a publication record, a pre-grant publication is not a granted patent, and the expiration figure is a naive 20-year arithmetic that models no PTA, terminal disclaimer, or maintenance lapse. Not an FTO conclusion in either direction; it is the trigger for a real one. Note the connector rejects the claim's US20150313608A1 spelling and needs the epodoc form. — source: patent US2015313608 → verified, EPO OPS published-data/publication epodoc=US2015313608 (patent US20150313608A1 → unconfirmed: "No EPO OPS record found" — format, not absence).
FTO — coverage of the search: beyond the single publication number in the preceding claim, no patent search was performed; the FTO field is otherwise unexamined. No landscape search of posture-sensing compression, servo-controlled pneumatic bladder control, or abdominal-compression-for-hypotension art was conducted, and no assignee search was run against intermittent pneumatic compression incumbents.
jurisdiction: US — confidence: unconfirmed — note: still true after this pass, and this pass did not change it. patent is an identifier lookup, not a landscape search — it resolves a number a human supplies and cannot enumerate art nobody has named, so no Verifier run can close this claim. One data point on what a…the full check landscape would find: an incidental lookup of US9295605 ("Methods and systems for auto-calibration of a pneumatic compression device", filed 2013-12-02, naive expiry 2033-12-02) confirms adjacent servo/pneumatic-control art exists and is live — recorded here as an illustration of unexamined field, not as a finding about this candidate. A real FTO opinion is outside counsel work and Tier 3. — source: no runnable invocation that could close it — patent resolves named numbers only; illustrative lookup patent US9295605 → verified, EPO OPS published-data/publication epodoc=US9295605.
Assumption, not a fact: adults with Parkinson disease, multiple system atrophy or pure autonomic failure — a population in which tremor, rigidity, bradykinesia and impaired dexterity are common — would be able and willing, with or without caregiver help, to don, charge, and operate a powered abdominal compression garment daily over a sustained period rather than abandoning it after an initial trial.
jurisdiction: US — confidence: unconfirmed — note: permanently unconfirmed absent primary research. The connector is explicit that a model's own estimate of stakeholder behaviour is a fabricated claim, and I have not produced one. The checkable proxy worth commissioning is device-abandonment or adherence data from the…the full check binder trials themselves: NCT01971008 has posted results (hasResults=true, claim 7verified) and NCT03482297 measured upright time as a secondary outcome — but both are short inpatient/study-day protocols, so neither measures sustained home use, which is what this claim actually asserts. — source: adoption "adults with Parkinson disease, MSA or PAF would be able and willing to don, charge and operate a powered abdominal compression garment daily over a sustained period" → unverifiable: "needs primary research (interviews, survey, published preference study)".
Assumption, not a fact: neurologists and autonomic specialists managing symptomatic neurogenic orthostatic hypotension would prescribe a device in an indication currently managed with midodrine and droxidopa, and would accept the documentation burden of a DME (durable medical equipment) prescription and prior authorization to do so.
jurisdiction: US — confidence: unconfirmed — note: permanently unconfirmed absent primary research, and not answerable by me. The rescoping the connector suggests is available and worth doing: the documentation burden half has a concrete proxy in NCD 280.6's own conditions of coverage (claim 9verified) — a four-week…the full check documented conservative-therapy trial for lymphedema, six months for CVI ulcers, physician oversight, a written treatment plan defining pressure and frequency, and ongoing monitoring. That is the shape of the burden a prescriber in an adjacent indication already carries, and it is a fact rather than an opinion. The willingness half needs interviews or a preference study. — source: adoption "neurologists and autonomic specialists would prescribe a device in an indication currently managed with midodrine and droxidopa and accept DME prior-authorization burden" → unverifiable: "needs primary research".
Assumption, not a fact: patients and prescribers would treat the absence of supine pressure exposure — compression applied only while upright — as a clinically meaningful advantage over pressor drug therapy sufficient to change prescribing, rather than as a theoretical distinction.
jurisdiction: US — confidence: unconfirmed — note: permanently unconfirmed absent primary research. Worth recording what the retrieved evidence does and does not say about the premise underneath the preference: PMID 27271310 (claim 5verified) reports that "Only midodrine increased seated SBP (31±5 versus 9±4 placebo and 7±5…the full check binder, P=0.003)", which is direct support for the mechanistic premise that the binder does not raise seated pressure the way midodrine does — the file's own caveat that the study did not measure supine BP outcomes still stands, and seated is not supine. The premise is better evidenced than the file allows; the preference built on it remains unevidenced, and that is what this claim asserts. — source: adoption "patients and prescribers would treat absence of supine pressure exposure as a clinically meaningful advantage sufficient to change prescribing" → unverifiable: "needs primary research"; mechanistic context from literature-detail 27271310 → found (claim 5verified).
Mechanism and clinical-risk reasoning (Generator's own, flagged as reasoning rather than finding): applying 40 mmHg abdominal compression only during upright posture is expected to raise standing blood pressure by reducing splanchnic venous pooling while producing zero supine pressure exposure by construction; the named failure modes are posture-detection error (compression applied while recumbent, or not applied on standing), pressure-sensing or vent failure, skin and abdominal-wall injury under sustained pressure, interference with respiration or with abdominal stomas/feeding tubes in comorbid patients, and reduced effectiveness in patients with high BMI. None of these has been characterized for this device because this device does not exist.
jurisdiction: US — confidence: unconfirmed — note: no connector resolves a failure-mode analysis for an unbuilt device, and the claim says so itself. The first clause — that the mechanism raises upright BP — is separately supported by claim 5verified's retrieved abstract ("orthostatic tolerance ... improved similarly with…the full check binder and midodrine (AUCSBP, 195±35 and 197±41 versus 19±38 mm Hg×minute for placebo; P=0.003)"), but that is a finding about the Vanderbilt investigational device, not about this one. The five named failure modes are uncharacterized in both directions and stay that way until a bench programme exists. A MAUDE (Manufacturer and User Facility Device Experience) sweep of product code JOW would give adjacent-device harm patterns, but MAUDE is a window scan with no denominator and produces no confidence tag — it would inform a Stage 7 plan, not this claim. — source: no runnable invocation — failure modes of an unbuilt device are outside every connector; mechanism context from literature-detail 27271310 → found (claim 5verified).
Assumption, not a fact: a home-use, patient-owned, prescription abdominal compression device of this description would fall within the Medicare durable medical equipment benefit category and be separately billable in its own right, rather than being packaged into another payment. The Generator asserts this as design intent; the benefit-category question is decided by CMS, not by the device's form factor.
jurisdiction: US — confidence: unconfirmed — note: unconfirmed, and the claim correctly names why — benefit-category determination is a CMS judgment, not a database lookup. Two adjacent facts now on record that bear on it without settling it: NCD 280.6 (claim 9verified) establishes that pneumatic compression devices are…the full check covered in the home setting under the DME benefit for other indications, which is the nearest precedent; and claim 13verified confirms that separate payability is an explicit RAPID eligibility criterion, so the exposure this assumption creates is real. The code-level check that would narrow it (coverage, hcpcs) is unavailable in this environment for missing data files. — source: adoption "a home-use patient-owned prescription abdominal compression device would fall within the Medicare DME benefit category and be separately billable" → unverifiable; coverage E0650 → unconfirmed: "No local cache at data/medicare_coverage_policies.csv"; precedent context from ncd 280.6 --jurisdiction US → verified (claim 9verified).
Assumption, not a fact: a pivotal study in symptomatic neurogenic orthostatic hypotension due to primary autonomic failure would enroll a cohort that is predominantly Medicare-aged, such that Medicare-population clinical outcomes could be designed into the protocol from the start. The Generator asserts no age-distribution figure and cites no registry.
jurisdiction: US — confidence: unconfirmed — note: no connector answers what a future cohort would look like. The closest real anchor now on record is the eligibility range of the two registered binder studies: NCT03482297 enrolled ages 40-80 and NCT01971008 ages 40-90 (claims 6 and 7) — both ranges straddle…the full check 65 rather than sitting above it, so the registry evidence neither confirms nor refutes "predominantly Medicare-aged" and is mildly cautionary about assuming it. An actual age distribution would need the trials' posted baseline characteristics or a CCW/registry pull, neither of which a connector here reaches. — source: adoption "a pivotal study in symptomatic nOH due to primary autonomic failure would enroll a predominantly Medicare-aged cohort" → unverifiable: "needs primary research"; eligibility-range context from trial-detail NCT03482297 and trial-detail NCT01971008 → found (claims 6, 7).
No competitor company was identified by the Generator as currently pursuing FDA clearance, De Novo authorization, or US commercialization of a powered, posture-triggered abdominal compression device for orthostatic hypotension.
jurisdiction: US — confidence: unconfirmed — note: nothing in this pass contradicts the claim and nothing in this pass can establish it. The 510(k) device-name searches at claim 3unconfirmed returned no OH-indicated abdominal compression device; the De Novo half could not be checked at all (missing data/fda_denovo.csv); and no…the full check connector in this repo reads company, financing, or FDA registration-and-listing data, which is where a pre-clearance entrant would be visible. The claim's own caveat is the right one and should survive into any Factor 8 reasoning: an absence in a search is not an absence in the market. Note also that the named academic work is not competition-free — the Vanderbilt IP (intellectual property) family at claim 26verified is listed as available for license, which is a route for an entrant as much as for this candidate. — source: 510k "orthostatic hypotension" --jurisdiction US → unconfirmed: "No 510(k) record found"; denovo "abdominal compression" --jurisdiction US → unconfirmed: "No local cache at data/fda_denovo.csv" (superseded); no connector exists for company/financing data; Verifier 2026-09-29 re-check, tag holds at unconfirmed: denovo "abdominal compression" --jurisdiction US → refuted: "No granted De Novo request matching 'abdominal compression' in the cached FDA De Novo listing (494 records)". Polarity: the connector refutes the existence of a matching grant, which is consistent with this claim, not a refutation of it. It still cannot establish the claim: the listing is matched on device name, and a pre-clearance entrant has no grant to find at all.
No domain dossier exists in this repo for orthostatic hypotension, autonomic failure, or Parkinson-disease autonomic complications: knowledge-base/domains/ as of 2026-09-18 contains README.md, _template.md, and twelve dossiers covering other clinical areas (canine/equine distal-limb wounds, chronic subjective tinnitus, ctDNA (circulating tumour DNA) MRD (molecular residual disease) assay validation, feline CKD (chronic kidney disease) subcutaneous fluids, internal hemorrhoids, lower-extremity lymphedema compression, neonatal hyperbilirubinemia home phototherapy, pediatric persistent asthma home monitoring, pediatric obstructive sleep apnea testing, potassium monitoring in CKD, stress urinary incontinence, veterinary diabetes glucose monitoring) — none for this clinical area.
jurisdiction: US — confidence: verified — note: re-read independently on 2026-09-18 and the listing matches the claim exactly — README.md, _template.md, and twelve dossiers with those twelve subjects, none touching orthostatic hypotension or autonomic failure. This is a repo-state check verified against the repository…the full check itself rather than a connector; it is evidence for no rubric factor and remains a research-lane trigger, as the claim says. — source: directory listing of knowledge-base/domains/, read by the Verifier 2026-09-18 — no connector applies (repo state, not a primary external source).
Adults with symptomatic neurogenic orthostatic hypotension, or their families, will accept and pay the out-of-pocket amount that remains after any Medicare Part B (Medicare Part B) durable-medical-equipment payment for a posture-triggered abdominal compression device.
jurisdiction: US — confidence: unconfirmed — note: class 3 (stakeholder future) — permanently unconfirmed absent primary research; the adoption connector returns unverifiable by design and I have not supplied a judgment of my own. The revealed-behaviour twin that would move it is published out-of-pocket abandonment…the full check data for a comparable DME purchase, which nobody has cited. — source: deck-surfaced assumption (desirability deck, 2026-09-20) — never checked; recorded so the Verifier can see it — evidence class 3 (stakeholder future); Verifier 2026-09-28: adoption "Adults with symptomatic nOH or their families will accept and pay the out-of-pocket amount remaining after Medicare Part B DME payment" → unverifiable: "asserts what clinicians, payers, or patients would do. No free, authoritative ... source"
A DMEPOS supplier will stock, deliver, fit and bill a prescription posture-triggered abdominal compression device for neurogenic orthostatic hypotension in the absence of a device-specific HCPCS code.
jurisdiction: US — confidence: unconfirmed — note: class 3 (stakeholder future) — permanently unconfirmed; what a supplier would do is not in any database. The code-existence premise underneath it is also unreachable here: hcpcs has no data/hcpcs_level_ii.csv (see claim 40unconfirmed). — source: deck-surfaced assumption…the full check (desirability deck, 2026-09-20) — never checked; recorded so the Verifier can see it — evidence class 3 (stakeholder future); Verifier 2026-09-28: adoption "A DMEPOS supplier will stock, deliver, fit and bill the device without a device-specific HCPCS code" → unverifiable: "asserts what clinicians, payers, or patients would do. No free, authoritative ... source"
A patient with symptomatic neurogenic orthostatic hypotension will perceive a reduction in orthostatic symptoms within the first weeks of home use large enough that they keep using the device rather than abandoning it.
jurisdiction: US — confidence: unconfirmed — note: class 3 (stakeholder future) — permanently unconfirmed. Adjacent class-2 context now on record, none of it about this device or home use: claim 65verified (midodrine persistence), claims 70-72 (compression-garment non-use and discomfort). — source: deck-surfaced assumption…the full check (desirability deck, 2026-09-20) — never checked; recorded so the Verifier can see it — evidence class 3 (stakeholder future); Verifier 2026-09-28: adoption "A patient will perceive symptom reduction in the first weeks of home use large enough to keep using the device" → unverifiable: "asserts what clinicians, payers, or patients would do. No free, authoritative ... source"
Adults with primary autonomic failure will tolerate sustained abdominal compression at the prescribed set pressure during every upright period of the day without abdominal discomfort, breathlessness or skin irritation sufficient to make them stop using it.
jurisdiction: US — confidence: unconfirmed — note: class 3 (stakeholder future) — permanently unconfirmed. Adjacent tolerability data now verified but all short-exposure: claim 74verified (1 of 19 had mild discomfort at 40 mmHg, study-day exposure only), claim 57verified (1 of 13 GERD exacerbation over 4 weeks, elastic binder), claim…the full check 59 (0 AEs, single study day). None measures every-upright-period daily use. — source: deck-surfaced assumption (desirability deck, 2026-09-20) — never checked; recorded so the Verifier can see it — evidence class 3 (stakeholder future); Verifier 2026-09-28: adoption "Adults with primary autonomic failure will tolerate sustained abdominal compression during every upright period without stopping use" → unverifiable: "asserts what clinicians, payers, or patients would do. No free, authoritative ... source"
CMS will assign a HCPCS Level II code under which a powered, posture-triggered abdominal compression device indicated for neurogenic orthostatic hypotension can be billed — either a new code or an existing pneumatic-compressor family code accepted for this device.
jurisdiction: US — confidence: unconfirmed — note: a future CMS coding action; no connector answers what CMS will do, and that is the half that decides the tag. Verifier re-run 2026-09-29 against data/hcpcs_level_ii.csv (CMS October 2026 release): the present-tense half is verified. The pneumatic-compressor family…the full check exists: E0650, E0651 and E0652 (compressors), E0655 (half-arm appliance), and E0656 and E0657 (trunk and chest appliances), none with a termination date. E1399 "Durable medical equipment, miscellaneous" also exists as a not-otherwise-classified route. None of this shows that CMS or a DME MAC (durable medical equipment Medicare administrative contractor) would accept this device under any of these codes, that any of them pays enough for the controller plus garments, or that any coverage policy reaches an nOH indication. Code existence is not billability. Tag stays unconfirmed. — source: deck-surfaced assumption (viability deck, 2026-09-20) — never checked; recorded so the Verifier can see it; Verifier 2026-09-28: hcpcs E0650 --jurisdiction US → unconfirmed: "No local cache at data/hcpcs_level_ii.csv ... Do not substitute a web search for this file."; hcpcs E0656 --jurisdiction US → unconfirmed (same missing file) (both superseded); Verifier 2026-09-29: hcpcs E0650|E0651|E0652|E0655|E0656|E0657|E1399 --jurisdiction US → verified, source_ref "local cache of CMS HCPCS Level II file, code=<code>"
A Medicare national coverage determination or DME MAC local coverage policy will reach automated abdominal compression for symptomatic neurogenic orthostatic hypotension, an indication NCD 280.6 does not cover.
jurisdiction: US — confidence: unconfirmed — note: a future coverage action; no connector answers what CMS or a DME MAC will do. Present state re-read today: NCD 280.6 text still names only lymphedema and CVI with venous stasis ulcers and describes a limb garment; the word 'orthostatic' does not appear (phrase miss is…the full check unconfirmed by design; the absence is the finding, as at claim 9verified). The code-keyed LCD (local coverage determination) index is unavailable (missing file). — source: deck-surfaced assumption (viability deck, 2026-09-20) — never checked; recorded so the Verifier can see it; Verifier 2026-09-28: ncd 280.6 --expect "orthostatic" --jurisdiction US → unconfirmed: "exists and was read, but its text does NOT contain the phrase 'orthostatic'", CMS Pub. 100-3 Medicare NCD Manual, chapter 1 part 4 (Rev. 13808, issued 05-29-26), section=280.6; coverage E0650 --jurisdiction US → unconfirmed: "No local cache at data/medicare_coverage_policies.csv"
No Medicare revenue can be billed for this device until De Novo authorization, HCPCS code assignment, and a coverage determination reaching orthostatic hypotension are all in place, and those three steps cannot be substantially run in parallel.
jurisdiction: US — confidence: unconfirmed — note: a sequencing/interpretation claim about Medicare billing prerequisites; no connector reads CMS benefit-category or claims-processing practice, and a regulation or NCD lookup would not settle how CMS applies them. Left for a human reimbursement read. — source:…the full check deck-surfaced assumption (viability deck, 2026-09-20) — never checked; recorded so the Verifier can see it; Verifier 2026-09-28: no runnable invocation — billing-prerequisite sequencing is outside every connector
The patent family published as US2015313608 (compression for decreasing abdominal venous pooling) is available for exclusive license to a single commercial developer.
jurisdiction: US — confidence: unconfirmed — note: license availability and exclusivity are not in any patent-bibliographic record. patent re-confirms only that the publication exists, is on-mechanism by title, and is live on a naive 20-year term (filed 2013-11-04, naive expiry 2033-11-04, no…the full check PTA/terminal-disclaimer/lapse modelled). Whether it is available to license, and on what terms, needs a direct enquiry to the rights holder (Tier 3). — source: deck-surfaced assumption (viability deck, 2026-09-20) — never checked; recorded so the Verifier can see it; Verifier 2026-09-28: patent US2015313608 → verified, EPO OPS published-data/publication epodoc=US2015313608 (dates only — does not reach licensing status)
Most US adults with symptomatic neurogenic orthostatic hypotension due to primary autonomic failure who would be prescribed this device are Medicare beneficiaries, so Medicare Part B is the payer for the majority of units.
jurisdiction: US — confidence: unconfirmed — note: payer-mix claim with no connector; market returns unverifiable by design. Partial age proxies now verified, none a payer-mix figure: claim 58verified (NCT01971008, Austrian cohort, median age 69, 12 of 15 aged 65+), claim 59verified (NCT04620382, mean age 71), claim 83verified (MarketScan…the full check PD+nOH mean age 77). Against that, claim 80verified counts MSA from age 30 and claim 87verified's MSA subgroup had mean age 63 (range 43-80), so a material under-65 share is plausible in MSA. Age 65+ is also not the same as Part B FFS (Medicare Advantage excluded). — source: deck-surfaced assumption (viability deck, 2026-09-20) — never checked; recorded so the Verifier can see it; Verifier 2026-09-28: market "Most US adults with symptomatic nOH due to primary autonomic failure prescribed this device are Medicare beneficiaries" → unverifiable: "no free, authoritative, machine-queryable source"
A posture-triggered abdominal compression device reaches its prescribed set pressure quickly enough after a detected transition to upright to blunt orthostatic symptom onset in patients with neurogenic orthostatic hypotension.
jurisdiction: US — confidence: unconfirmed — note: performance property of an unbuilt device; no connector resolves it. Nearest verified anchor is claim 73verified (the Vanderbilt binder inflated or deflated in under 30 seconds), and that was a manually activated device, so it says nothing about posture-detection latency. —…the full check source: deck-surfaced assumption (feasibility deck, 2026-09-20) — never checked; recorded so the Verifier can see it; Verifier 2026-09-28: no runnable invocation — engineering property of an unbuilt device
This candidate's own bladder geometry and servo control loop reproduce the standing-tolerance and symptom-burden effect that PMID 27271310 reports for the Vanderbilt investigational automated abdominal binder.
jurisdiction: US — confidence: unconfirmed — note: the device does not exist; no connector can say whether it will reproduce another device's result. Note what claim 73verified establishes: the PMID 27271310 effect was produced with manual activation <2 min before standing and ≤10 min of standing, not with posture triggering…the full check or all-day use. — source: deck-surfaced assumption (feasibility deck, 2026-09-20) — never checked; recorded so the Verifier can see it; Verifier 2026-09-28: no runnable invocation — unbuilt device
FDA will require a clinical investigation under an IDE, rather than bench, biocompatibility and human-factors data alone, before authorizing an orthostatic-hypotension treatment claim for this device.
jurisdiction: US — confidence: unconfirmed — note: a prediction of an FDA evidentiary judgment; no connector reads FDA guidance or pre-submission feedback, and the answer depends on the pathway (claims 1-3) which is itself open. Only a Q-Sub settles it. — source: deck-surfaced assumption (feasibility deck, 2026-09-20)…the full check — never checked; recorded so the Verifier can see it; Verifier 2026-09-28: no runnable invocation — FDA review judgment is outside every connector
A torso-mounted accelerometer or inclinometer can discriminate upright from seated and recumbent posture in adults with Parkinson disease or multiple system atrophy, including those with stooped posture or camptocormia, at a false-inflation rate low enough for a safety case that rests on zero supine pressure exposure.
jurisdiction: US — confidence: unconfirmed — note: engineering feasibility of an unbuilt sensor function. Adjacent class-2 evidence now verified: claim 85verified (multi-sensor method, high sensitivity/specificity reported without figures, 10 PD patients) and claim 84verified (camptocormia 15.6% in a Chinese MSA cohort), neither of…the full check which gives a false-inflation rate for a single torso sensor. — source: deck-surfaced assumption (feasibility deck, 2026-09-20) — never checked; recorded so the Verifier can see it; Verifier 2026-09-28: no runnable invocation — unbuilt device
A bench rig can demonstrate that the device vents to zero pressure under single-fault conditions — pump runaway, pressure-sensor failure, or loss of the posture signal — fast enough to prevent sustained compression while the wearer is recumbent.
jurisdiction: US — confidence: unconfirmed — note: bench outcome for an unbuilt device; no connector answers it. The adjacent registry fact at claim 56unconfirmed (JOW recalls for high-pressure errors from a software-logic change) shows the failure class is real in marketed pneumatic devices. — source: deck-surfaced assumption…the full check (feasibility deck, 2026-09-20) — never checked; recorded so the Verifier can see it; Verifier 2026-09-28: no runnable invocation — unbuilt device
A garment platform in a small number of stock sizes can deliver the prescribed splanchnic set pressure across the body-habitus range of adults with primary autonomic failure, without per-patient custom manufacture.
jurisdiction: US — confidence: unconfirmed — note: design feasibility of an unbuilt garment; no connector answers it. — source: deck-surfaced assumption (feasibility deck, 2026-09-20) — never checked; recorded so the Verifier can see it; Verifier 2026-09-28: no runnable invocation — unbuilt device
openFDA device classification lists product code LHX, 'Trousers, Anti-Shock', as a Class II device under regulation 870.5800, the same regulation that carries product code JOW.
jurisdiction: US — confidence: verified — note: every element matches the registry record: product code LHX, 'Trousers, Anti-Shock', device class 2, regulation 870.5800, review panel CV; JOW re-checked under the same regulation. Checked against this file's intended_use (home prescription device for symptomatic nOH in…the full check primary autonomic failure): this confirms only that an anti-shock trouser code sits under 870.5800. It does not show that 870.5800 reaches a posture-triggered nOH treatment device, which remains the open SE question at claim 2verified. — source: research lane, from dossier neurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source: FDA product code LHX (openFDA device/classification) — evidence class 1 (registry fact); not independently checked — Verifier to confirm against the primary source; Verifier 2026-09-28: classification --product-code LHX --jurisdiction US → verified, openFDA device/classification product_code=LHX; classification --product-code JOW --jurisdiction US → verified, openFDA device/classification product_code=JOW (regulation 870.5800)
openFDA device classification lists product code PPS, 'Sleeve, Head And Neck, Compressible', as a Class II device under regulation 870.5800, so that regulation already carries at least two product codes that are not limb sleeves (LHX and PPS).
jurisdiction: US — confidence: verified — note: PPS returns 'Sleeve, Head And Neck, Compressible', device class 2, regulation 870.5800, panel CV, so with LHX (claim 51verified) 870.5800 carries at least two non-limb product codes, as claimed. Checked against this file's intended_use: this shows that FDA has classified…the full check non-limb compression under a regulation whose text says 'limb'. It does not show that an nOH treatment claim fits there (claim 2verified). — source: research lane, from dossier neurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source: FDA product code PPS (openFDA device/classification) — evidence class 1 (registry fact); not independently checked — Verifier to confirm against the primary source; Verifier 2026-09-28: classification --product-code PPS --jurisdiction US → verified, openFDA device/classification product_code=PPS
510(k) K874774, 'TROUSERS, PNEUMATIC, ANTI-SHOCK THREE BLADDERS' (Vinyl Technology, Inc.), was cleared under product code LHX on 1988-02-08, and 510(k) K953763, 'GLADIATOR ANTISHOCK PANTS' (Jobst Institute, Inc.), under LHX on 1995-11-28; these are the only two LHX clearances decided between 1986-10-08 and 2026-09-28. Whether either device compresses the abdomen is not stated in the registry record.
jurisdiction: US — confidence: unconfirmed — note: the two named clearances are real, and the names, applicants and decision dates match (K874774, Vinyl Technology, Inc., 1988-02-08; K953763, Jobst Institute, Inc., 1995-11-28). The product-code attribution and the 'only two in window' enumeration rest on a…the full checkclearances window scan: it returned 4 LHX clearances since 1976 (total_matches=4, truncated=false), both of these plus K841605 (1984-07-06) and K812564 (1981-10-23), which fall before the claim's window. That is consistent with the claim, but a ScanResult carries no tag, and no point connector answers product code or enumeration. No 510(k) summary exists for either K-number, so what they were cleared to do, and whether they compress the abdomen, remains unknown, as the claim itself says. — source: research lane, from dossier neurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source: K874774; K953763 — evidence class 1 (registry fact); not independently checked — Verifier to confirm against the primary source; Verifier 2026-09-28: 510k "TROUSERS, PNEUMATIC, ANTI-SHOCK THREE BLADDERS" --applicant "Vinyl Technology" --jurisdiction US → verified, openFDA device/510k k_number=K874774; 510k "GLADIATOR ANTISHOCK PANTS" --applicant "Jobst" --jurisdiction US → verified, openFDA device/510k k_number=K953763; clearance-summary K874774 --jurisdiction US → unconfirmed: "No 510(k) summary PDF found for K874774"; clearance-summary K953763 --jurisdiction US → unconfirmed: "No 510(k) summary PDF found for K953763"; enumeration from scan only (clearances --product-code LHX --since 1976-01-01, found, 4 records, no tag)
21 CFR 890.3490 (Truncal orthosis) is Class I, exempt from premarket notification, names abdominal orthoses among its examples, and identifies the device as intended to support or immobilize fractures, strains, or sprains of the neck or trunk; openFDA product code KTD, 'Orthosis, Abdominal', is classified under it. The regulation text names no haemodynamic or orthostatic indication.
jurisdiction: US — confidence: verified — note: eCFR returns the full section and each element is in it: 'Class I (general controls)'; 'exempt from the premarket notification procedures ... subject to the limitations in § 890.9'; 'Abdominal' is the first listed example; the identification reads 'to support or to…the full check immobilize fractures, strains, or sprains of the neck or trunk'. KTD = 'Orthosis, Abdominal', class 1, regulation 890.3490, panel PM. The absence half holds on the full text: 'orthostatic' is not in it (phrase miss is unconfirmed by design; the absence is the finding). Checked against this file's intended_use: the identification is musculoskeletal, and the § 890.9 limitations on exemption apply to a device with a different intended use, so this route does not carry an nOH claim. That supports the file's description of route 3 as a claim-stripped floor. — source: research lane, from dossier neurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source: 21 CFR 890.3490; FDA product code KTD — evidence class 1 (registry fact); not independently checked — Verifier to confirm against the primary source; Verifier 2026-09-28: regulation 890.3490 --expect "Class I" --jurisdiction US → verified, eCFR versioner title-21, issue 2026-09-22, section=890.3490; regulation 890.3490 --expect "abdominal" --jurisdiction US → verified, same; regulation 890.3490 --expect "fractures, strains, or sprains of the neck or trunk" --jurisdiction US → verified, same; regulation 890.3490 --expect "exempt from the premarket notification" --jurisdiction US → verified, same; regulation 890.3490 --expect "orthostatic" --jurisdiction US → unconfirmed: "exists but its text does NOT contain the phrase 'orthostatic'"; classification --product-code KTD --jurisdiction US → verified, openFDA device/classification product_code=KTD
No granted De Novo request in the FDA De Novo listing (494 records, retrieved 2026-09-24) has a device name matching 'abdominal compression', 'abdominal binder', 'orthostatic', 'splanchnic' or 'compression garment'. This is a device-name search, not an indication search.
jurisdiction: US — confidence: verified — note: POLARITY: the connector's refuted is on the proposition 'a granted De Novo matching X exists'. This claim asserts the opposite, so each refuted below confirms it. The tag is not a softened refutation. The cache is the file the claim names: sha256 c95e264f…7cfd…the full check matches, 494 records. All five terms return no match, and a case-insensitive grep of the file for 'abdomin', 'orthostat', 'splanchn' or 'compression' finds 0 lines. This also closes the De Novo half that claim 3unconfirmed could not check. The limit stands as the claim states it: this is a device-name search, it cannot see a differently named grant with an OH indication, and it says nothing about 510(k) or PMA. — source: research lane, from dossier neurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source: FDA De Novo database, accessdata.fda.gov denovo.cfm listing cached as data/fda_denovo.csv (sha256 c95e264f400a665befd5679f20b2ef2c813b5f1ca8fdb0e3e19832f471f77cfd) — evidence class 1 (registry fact); not independently checked — Verifier to confirm against the primary source; Verifier 2026-09-28: denovo "abdominal compression" --jurisdiction US → refuted: "No granted De Novo request matching 'abdominal compression' in the cached FDA De Novo listing (494 records)", local cache of FDA De Novo listing (no match); denovo "abdominal binder" --jurisdiction US → refuted (same); denovo "orthostatic" --jurisdiction US → refuted (same); denovo "splanchnic" --jurisdiction US → refuted (same); denovo "compression garment" --jurisdiction US → refuted (same)
FDA recalls Z-1917-2025, Z-1918-2025 and Z-1919-2025 (Cardinal Health Kendall SCD compression sleeves, product code JOW) give the reason 'Incorrect software logic may cause frequent E1 errors (system high pressure)' with FDA root cause 'Software change control'.
jurisdiction: US — confidence: unconfirmed — note: the text matches: a recalls window scan of JOW (2025-01-01 to 2026-09-28) returns Z-1917-2025, Z-1918-2025 and Z-1919-2025, all Cardinal Health 200, LLC Kendall SCD sleeves, initiated 2025-05-13, status Completed, reason 'Incorrect software logic may cause frequent…the full check E1 errors (system high pressure). Issue may cause delay in treatment or therapy.', FDA root cause 'Software change control', related 510(k) K230028. There is no point-lookup connector for a recall record, though, and a window scan is a ScanResult that cannot carry a tag, so this stays unconfirmed pending the queued scan-supported decision or a recall point connector. Scan-supported, not verified. — source: research lane, from dossier neurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source: FDA recall Z-1917-2025; Z-1918-2025; Z-1919-2025 — evidence class 1 (registry fact); not independently checked — Verifier to confirm against the primary source; Verifier 2026-09-28: no tag-bearing invocation — recall records are reachable only by scan (recalls --product-code JOW --since 2025-01-01, found, openFDA device/recall product_res_number=Z-1917-2025 / Z-1918-2025 / Z-1919-2025)
ClinicalTrials.gov NCT01971008 posted results report 15 participants started and 12 completed the elastic abdominal binder crossover, with all 3 non-completions recorded as 'Protocol Violation', and 1 of 13 participants at risk reporting gastro-oesophageal reflux exacerbation during the 4-week open-label binder phase; no serious adverse events.
jurisdiction: US — confidence: verified — note: posted results read from the registry record the connector points to (ClinicalTrials.gov API v2, resultsSection); trial-detail itself returns protocol fields only. Participant flow: STARTED 6+9=15, COMPLETED 4+8=12, NOT COMPLETED 2+1=3, dropWithdraws all 'Protocol…the full check Violation'. Adverse events: elastic binder 'otherNumAffected 1 / otherNumAtRisk 13', term 'Gastro-esophageal reflux', note 'exacerbation ... during the 4-weeks open-label follow-up'; serious 0/13 binder, 0/12 placebo. Sponsor-reported and unappraised. Region of Enrollment is Austria (sponsor Medical University Innsbruck), so this is non-US clinical activity under a US-registry jurisdiction tag. — source: research lane, from dossier neurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source: NCT01971008 — evidence class 1 (registry fact); not independently checked — Verifier to confirm against the primary source; Verifier 2026-09-28: trial-detail NCT01971008 → found, ClinicalTrials.gov NCTId=NCT01971008 (hasResults=true), https://clinicaltrials.gov/study/NCT01971008; results read from https://clinicaltrials.gov/api/v2/studies/NCT01971008
ClinicalTrials.gov NCT01971008 posted baseline characteristics report a median age of 69 years (IQR 66-75), with 12 of 15 participants aged 65 or older.
jurisdiction: US — confidence: verified — note: baseline module: Age, Continuous, MEDIAN 69, IQR 66-75 (total n=15); Age, Categorical, '>=65 years' 12 of 15 (3 aged 18-65). One oddity a reader should know: the same median and IQR (69, 66-75) are posted for each arm and for the total, which suggests a data-entry…the full check shortcut rather than arm-level values. The cohort is Austrian, not US. — source: research lane, from dossier neurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source: NCT01971008 — evidence class 1 (registry fact); not independently checked — Verifier to confirm against the primary source; Verifier 2026-09-28: trial-detail NCT01971008 → found, ClinicalTrials.gov NCTId=NCT01971008; baseline read from https://clinicaltrials.gov/api/v2/studies/NCT01971008
ClinicalTrials.gov NCT04620382 posted results report 31 participants enrolled and 22 completing a single-blind crossover of one study day of 40 mmHg abdominal compression versus one study day of midodrine, with zero serious and zero other adverse events recorded in either arm among 22 at risk, and mean baseline age 71 years (SD 8).
jurisdiction: US — confidence: verified — note: registry: EARLY_PHASE1, RANDOMIZED, CROSSOVER, masking=SINGLE, enrollment 31 ACTUAL, sponsor Vanderbilt. Flow: STARTED 15+16=31, COMPLETED 11+11=22. Arms are active 40 mmHg abdominal compression + placebo pill versus midodrine 5-10 mg + sham compression (the claim omits…the full check the sham and placebo pairing). AEs: serious 0/22 and other 0/22 in both arms, deaths 0/22; AE time frame is enrollment to end of study day 2 (3-4 days). Mean age 71, SD 8, is over the 22 analysed, not the 31 enrolled. Primary outcome is Augmentation Index, a cardiovascular risk marker, not a symptom outcome. — source: research lane, from dossier neurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source: NCT04620382 — evidence class 1 (registry fact); not independently checked — Verifier to confirm against the primary source; Verifier 2026-09-28: trial-detail NCT04620382 → found, ClinicalTrials.gov NCTId=NCT04620382 (hasResults=true), https://clinicaltrials.gov/study/NCT04620382; results read from https://clinicaltrials.gov/api/v2/studies/NCT04620382
ClinicalTrials.gov NCT06039410 registers Isotech Ltd's ISO (International Organization for Standardization)-101 device for orthostatic hypotension in a single-group study with an ESTIMATED (not actual) enrollment of 30, status UNKNOWN, and no posted results.
jurisdiction: US — confidence: verified — note: every element is in the record: sponsor Isotech Ltd (INDUSTRY), device ISO-101, condition orthostatic hypotension, SINGLE_GROUP, masking NONE, enrollment 30 ESTIMATED (a registered target, not a count), status UNKNOWN, hasResults=false. Outcome windows are 24 hours. The…the full check record as returned gives no trial location. — source: research lane, from dossier neurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source: NCT06039410 — evidence class 1 (registry fact); not independently checked — Verifier to confirm against the primary source; Verifier 2026-09-28: trial-detail NCT06039410 → found, ClinicalTrials.gov NCTId=NCT06039410, https://clinicaltrials.gov/study/NCT06039410
The NORTHERA (droxidopa) prescribing information states 'Effectiveness beyond 2 weeks of treatment has not been established' and carries a boxed warning for supine hypertension.
jurisdiction: US — confidence: unconfirmed — note: unconfirmed for a tooling reason: this repo has no drug-label connector (no DailyMed or Drugs@FDA reader), the same gap as claim 11unconfirmed. Nothing was looked up in either direction and no web search was substituted. Indirect context only: claim 66verified (PMID 30949555) says there…the full check is 'limited information ... beyond two weeks of treatment', which is consistent with the quoted label language but is not the label. — source: research lane, from dossier neurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source: DailyMed SPL setid 2179f02c-48d7-48eb-8007-5ae43d8d16bc — evidence class 1 (registry fact); not independently checked — Verifier to confirm against the primary source; Verifier 2026-09-28: no runnable invocation — no connector reads DailyMed SPL setid 2179f02c-48d7-48eb-8007-5ae43d8d16bc
A current midodrine hydrochloride prescribing information states that midodrine 'should be continued only for patients who report significant symptomatic improvement', that its clinical benefits, principally improved ability to carry out activities of daily living, have not been verified, and that supine systolic pressures of about 200 mmHg were seen in about 13.4% of patients given 10 mg.
jurisdiction: US — confidence: unconfirmed — note: unconfirmed for a tooling reason: no drug-label connector exists in this repo (same gap as claim 11unconfirmed). Nothing was looked up and no web search was substituted. — source: research lane, from dossier neurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source:…the full check DailyMed SPL setid aec0d2de-ce83-b7c2-5d10-740607d50521 — evidence class 1 (registry fact); not independently checked — Verifier to confirm against the primary source; Verifier 2026-09-28: no runnable invocation — no connector reads DailyMed SPL setid aec0d2de-ce83-b7c2-5d10-740607d50521
Federal Register document 2019-23014 (84 FR 56459) records FDA's determination that PROAMATINE (midodrine hydrochloride) tablets were not withdrawn from sale for reasons of safety or effectiveness.
jurisdiction: US — confidence: verified — note: the determination is the document's own title as the Federal Register records it: 'Determination That PROAMATINE (Midodrine Hydrochloride) Tablets, 2.5 Milligrams, 5 Milligrams, and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness'…the full check (Notice, FDA, published 2019-10-22). The FR API abstract for the same document reads 'FDA ... has determined that PROAMATINE (midodrine hydrochloride) tablets ... were not withdrawn from sale for reasons of safety or effectiveness'. The --expect runs came back unconfirmed because of a CONNECTOR DEFECT, not the document: the full-text URL now returns a federalregister.gov bot-block 'Request Access' page (1,717 characters), which the connector reports as 'retrieved in full' and which does not even contain the word PROAMATINE from the title. Reproduced on 2026-16368 ('separately payable', verified 2026-09-18, now also unconfirmed at 1,717 chars). So every policy --expect in this repo is currently unreliable. — source: research lane, from dossier neurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source: Federal Register 2019-23014 (84 FR 56459) — evidence class 1 (registry fact); not independently checked — Verifier to confirm against the primary source; Verifier 2026-09-28: policy 2019-23014 --expect-type notice --jurisdiction US → verified, Federal Register document_number=2019-23014 (84 FR 56459); policy 2019-23014 --expect "not withdrawn from sale for reasons of safety or effectiveness" --jurisdiction US → unconfirmed: "retrieved in full (1,717 characters) and does not contain the phrase" (bot-block page, see note); abstract read from https://www.federalregister.gov/api/v1/documents/2019-23014.json; Verifier 2026-09-29 re-check, tag holds at verified: policy 2019-23014 --expect "not withdrawn from sale for reasons of safety or effectiveness" --jurisdiction US → verified, Federal Register document_number=2019-23014 (84 FR 56459), full text read from GovInfo (GPO official edition, https://www.govinfo.gov/content/pkg/FR-2019-10-22/html/2019-23014.htm); the phrase is found in the document's own title as printed ("...Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness ... ACTION: Notice"), which is the determination the claim describes. The bot-block defect in the note above no longer applies to this lookup.
In a retrospective US pharmacy-claims analysis (Symphony Health, mid-2014 to 2018; persistence = time to first coverage gap of 45 days or more, capped at 365 days), median treatment persistence was 303 days (95% CI 274-325) for droxidopa (n=2,305) versus 172 days (95% CI 169-176) for midodrine (n=117,243).
jurisdiction: US — confidence: verified — note: cold re-retrieval; every figure is in the abstract: Symphony Health database, mid-2014 to 2018, persistence 'time to the first break in drug coverage of ≥45 days ... capped at 365 days', droxidopa n=2305 and midodrine n=117,243, median '303 [274-325] vs 172 [169-176]…the full check days'. The midodrine cohort is 'OH' generally, not nOH, so the comparison is not like-for-like. Abstract only, unappraised. — source: research lane, from dossier neurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source: PMID 32200263 — evidence class 2 (published finding); not independently checked — needs a cold re-retrieval of the cited source by someone who did not draft this; Verifier 2026-09-28: literature-detail 32200263 → found, PubMed PMID=32200263 (efetch), https://pubmed.ncbi.nlm.nih.gov/32200263/
In a Tennessee Medicaid cohort of 1,704 orthostatic hypotension patients aged 50 or older (1996-2008), median persistence was 259 days (IQR 119-807) on midodrine and 254 days (IQR 119-783) on fludrocortisone, with discontinuation (90 days without medication) ending 25% of midodrine episodes; the causes of low persistence were not established.
jurisdiction: US — confidence: verified — note: cold re-retrieval; matches: 1704 OH patients aged ≥50, Tennessee Medicaid 1996-2008, discontinuation = '90 days without medication', episodes ended by discontinuation '25% midodrine', median persistence midodrine '259 (IQR: 119-807)' and fludrocortisone '254 (IQR:…the full check 119-783)', and 'Further research is warranted to determine the causes of this low persistence'. OH generally, not nOH specifically. Abstract only. — source: research lane, from dossier neurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source: PMID 24008021 — evidence class 2 (published finding); not independently checked — needs a cold re-retrieval of the cited source by someone who did not draft this; Verifier 2026-09-28: literature-detail 24008021 → found, PubMed PMID=24008021 (efetch), https://pubmed.ncbi.nlm.nih.gov/24008021/
In a US non-interventional prospective cohort of 179 patients newly started on droxidopa for nOH via a pharmacy hub, continuation rates were 87%, 79% and 75% at months 1, 3 and 6.
jurisdiction: US — confidence: verified — note: cold re-retrieval; matches: 'non-interventional, US-based, prospective cohort study utilized a pharmacy hub', '179 enrolled patients completed baseline surveys', continuation '87%, 79%, and 75%' at months 1, 3 and 6. The denominator is baseline completers, and the…the full check abstract gives no funding disclosure. Abstract only. — source: research lane, from dossier neurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source: PMID 30949555 — evidence class 2 (published finding); not independently checked — needs a cold re-retrieval of the cited source by someone who did not draft this; Verifier 2026-09-28: literature-detail 30949555 → found, PubMed PMID=30949555 (efetch), https://pubmed.ncbi.nlm.nih.gov/30949555/
Across droxidopa controlled and long-term open-label studies in symptomatic nOH, the incidence of treatment discontinuation due to blood-pressure-related events was approximately 2.5%.
jurisdiction: US — confidence: verified — note: cold re-retrieval; verbatim: 'The incidence of treatment discontinuation due to blood pressure-related events was approximately 2.5%.' PubMed types this as a Review pooling RCT (randomised controlled trial) and open-label data. Abstract only. — source: research lane, from dossier…the full checkneurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source: PMID 28159196 — evidence class 2 (published finding); not independently checked — needs a cold re-retrieval of the cited source by someone who did not draft this; Verifier 2026-09-28: literature-detail 28159196 → found, PubMed PMID=28159196 (efetch), https://pubmed.ncbi.nlm.nih.gov/28159196/
In a long-term open-label study of 350 nOH patients on droxidopa (mean exposure 363 days), rates of serious adverse events, cardiac-related adverse events and supine hypertension were 24%, 5% and 5% respectively.
jurisdiction: US — confidence: verified — note: cold re-retrieval; matches: 350 patients, 'Mean duration of droxidopa exposure was 363 days', SAE/cardiac/supine hypertension '24%, 5%, and 5%'. The study is 'multinational, open-label', so not a US-only cohort. Abstract only. — source: research lane, from dossier…the full checkneurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source: PMID 27614923 — evidence class 2 (published finding); not independently checked — needs a cold re-retrieval of the cited source by someone who did not draft this; Verifier 2026-09-28: literature-detail 27614923 → found, PubMed PMID=27614923 (efetch), https://pubmed.ncbi.nlm.nih.gov/27614923/
In the droxidopa phase 3 randomized withdrawal trial (n=162 randomized), supine systolic blood pressure above 180 mmHg was observed at endpoint in 4.9% of droxidopa and 2.5% of placebo recipients.
jurisdiction: US — confidence: verified — note: cold re-retrieval; matches: 'From randomization to endpoint (n = 162)', 'supine systolic BP >180 mm Hg was observed in 4.9% of droxidopa and 2.5% of placebo recipients'. Design context the claim omits: randomization was of open-label responders, over 7 days double-blind.…the full check Abstract only. — source: research lane, from dossier neurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source: PMID 24944260 — evidence class 2 (published finding); not independently checked — needs a cold re-retrieval of the cited source by someone who did not draft this; Verifier 2026-09-28: literature-detail 24944260 → found, PubMed PMID=24944260 (efetch), https://pubmed.ncbi.nlm.nih.gov/24944260/
In a UK survey of 67 older patients prescribed elastic compression stockings for orthostatic hypotension (74% response, mean age 75.1), 33% wore them daily and 43% never used them; 51% reported difficulty in application and 31% discomfort, with difficulty more likely at age 75 or older.
jurisdiction: US — confidence: unconfirmed — note: the figures all match the abstract: 67 patients responded, 74% response rate, mean age 75.1, '33% wore ECS daily ... 43% never used them', 51% difficulty in application, 31% discomfort, aged 75+ more likely to report difficulty (P=0.003). The 'UK' descriptor does not…the full check survive: the abstract names no country, and all five author affiliations on the PubMed record are in the Republic of Ireland (University Hospital Limerick; University of Limerick; NUI Galway). An affiliation is not proof of survey site, so this is not a formal refutation, but the record points away from UK. A restated claim without the geography, or with Ireland, would verify on these figures. — source: research lane, from dossier neurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source: PMID 25344314 — evidence class 2 (published finding); not independently checked — needs a cold re-retrieval of the cited source by someone who did not draft this; Verifier 2026-09-28: literature-detail 25344314 → found, PubMed PMID=25344314 (efetch), https://pubmed.ncbi.nlm.nih.gov/25344314/; affiliations read from efetch XML of the same PMID
In a qualitative study of 25 people over 60 with orthostatic hypotension who had tried compression stockings and abdominal compression in a phase II study, compression stockings were considered unacceptable by the majority because of the practicalities of applying and removing them and the stigma of their appearance, while views on abdominal compression were mixed.
jurisdiction: US — confidence: verified — note: cold re-retrieval; matches: '25 people aged over 60 years', all had experienced compression stockings and abdominal compression 'within a phase II study'; 'mixed views on acceptability of abdominal compression whereas compression stockings were considered unacceptable by…the full check the majority ... due to the practicalities of applying/removing the compression and the stigma attached to their appearance'. OH generally in older people, not nOH. Abstract only. — source: research lane, from dossier neurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source: PMID 30558552 — evidence class 2 (published finding); not independently checked — needs a cold re-retrieval of the cited source by someone who did not draft this; Verifier 2026-09-28: literature-detail 30558552 → found, PubMed PMID=30558552 (efetch), https://pubmed.ncbi.nlm.nih.gov/30558552/
In a survey of 358 people with POTS (n=330) or nOH (n=28) (mean age 37.9, 95% women), 13.4% reported abdominal compression as their most frequently used compression garment versus 65.4% leg compression and 20.1% shapewear, and abdominal compression was rated less comfortable than leg compression (mean 2.94 vs 3.05 on a 1-5 scale).
jurisdiction: US — confidence: verified — note: cold re-retrieval; matches: 330 POTS + 28 nOH, mean age 37.9, 95.0% women, most-frequent garment '65.4% vs. 20.1% vs. 13.4%' (leg, shapewear, abdominal), comfort '2.67 vs. 2.94 vs. 3.05' (shapewear, abdominal, leg; p=0.03). Relevance caveat: 92% of respondents have POTS,…the full check a young and mostly female population unlike this candidate's intended_use (older primary autonomic failure). Abstract only. — source: research lane, from dossier neurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source: PMID 39685762 — evidence class 2 (published finding); not independently checked — needs a cold re-retrieval of the cited source by someone who did not draft this; Verifier 2026-09-28: literature-detail 39685762 → found, PubMed PMID=39685762 (efetch), https://pubmed.ncbi.nlm.nih.gov/39685762/
In the published servo-controlled abdominal binder study (n=19 autonomic failure), both inflators were manually activated to about 40 mmHg less than 2 minutes before the orthostatic test rather than triggered by a posture sensor; inflation or deflation took under 30 seconds; and standing was tested for 10 minutes or less.
jurisdiction: US — confidence: verified — note: full text read; verbatim: 'Both inflators were manually activated to provide a compression level of ~40 mmHg <2 minutes before the post-intervention orthostatic tolerance test'; 'The time taken to inflate or deflate the bladder with either pump was <30 seconds';…the full check limitation 'we only tested responses to the inflatable binder during ≤10 minutes of standing'. Consequence: the abstract's 'can be activated only on standing' describes a capability, and the study itself did not use posture triggering. The candidate's defining feature (posture-triggered activation) therefore has no clinical precedent in this paper. — source: research lane, from dossier neurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source: PMID 27271310 (full text PMC4945429) — evidence class 2 (published finding); not independently checked — needs a cold re-retrieval of the cited source by someone who did not draft this; Verifier 2026-09-28: literature-detail 27271310 → found, PubMed PMID=27271310 (efetch), https://pubmed.ncbi.nlm.nih.gov/27271310/; full text read from NCBI efetch db=pmc id=4945429 (PMC4945429)
In the published servo-controlled abdominal binder study (n=19 autonomic failure), one subject reported mild abdominal discomfort at 40 mmHg that improved on deflation to 20 mmHg, and no other adverse events were reported with the binder.
jurisdiction: US — confidence: verified — note: full text read; verbatim under 'Adverse Events': 'One subject reported mild abdominal discomfort with a compression level of 40 mmHg, but deflation to a lower compression level (20 mmHg) improved the discomfort, and allowed the patient to complete the studies. All other…the full check patients tolerated the procedure and no other adverse events were reported with the binder.' Exposure was short study-day sessions only. — source: research lane, from dossier neurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source: PMID 27271310 (full text PMC4945429) — evidence class 2 (published finding); not independently checked — needs a cold re-retrieval of the cited source by someone who did not draft this; Verifier 2026-09-28: literature-detail 27271310 → found, PubMed PMID=27271310 (efetch), https://pubmed.ncbi.nlm.nih.gov/27271310/; full text read from NCBI efetch db=pmc id=4945429 (PMC4945429)
In a single-blind randomized crossover in 16 Parkinson disease patients with at least moderate symptomatic orthostatic hypotension, one week each of abdominal binder and compression stockings produced no significant change in real-life sit-to-stand frequency (the primary endpoint), while OHQ improved with the binder but not stockings.
jurisdiction: US — confidence: verified — note: cold re-retrieval; matches: 16 PD patients 'with at least moderate symptomatic OH', 'randomized, single-blinded, controlled, crossover', 1 week each; primary STS frequency 'CS 4.4 ... AB 3.6 ... without treatment 3.6 (p = 1.0)'; 'OHQ and SCOPA-AUT improved significantly…the full check with AB but not CS'. Abstract only. — source: research lane, from dossier neurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source: PMID 36278359 — evidence class 2 (published finding); not independently checked — needs a cold re-retrieval of the cited source by someone who did not draft this; Verifier 2026-09-28: literature-detail 36278359 → found, PubMed PMID=36278359 (efetch), https://pubmed.ncbi.nlm.nih.gov/36278359/
In a phase 2 study of 37 people aged 60 or older with orthostatic hypotension, a combination of bolus water drinking, physical counter-manoeuvres and abdominal compression raised standing systolic BP by 20 mmHg (95% CI 12-29) but had no significant effect on symptoms.
jurisdiction: US — confidence: verified — note: cold re-retrieval; matches: 37 people ≥60 with OH; Therapy B (bolus water + PCM + abdominal compression) 'increasing standing systolic BP by 20 mmHg (95% CI 12, 29)'; 'Neither therapy had a significant effect on symptoms'. OH generally, not nOH. Abstract only. — source:…the full check research lane, from dossier neurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source: PMID 31868889 — evidence class 2 (published finding); not independently checked — needs a cold re-retrieval of the cited source by someone who did not draft this; Verifier 2026-09-28: literature-detail 31868889 → found, PubMed PMID=31868889 (efetch), https://pubmed.ncbi.nlm.nih.gov/31868889/
In a randomized crossover in 13 adults with neurogenic orthostatic hypotension, 10 mmHg abdominal compression applied before rising blunted the standing systolic BP drop from -57 mmHg to -50 and -46 mmHg (conventional and adjustable binders), and increasing compression to subject-selected maximal tolerance once standing gave no additional benefit.
jurisdiction: US — confidence: verified — note: cold re-retrieval; matches: 'Adults with neurogenic OH (N=13)', randomized crossover; standing drop '-57mmHg' without binder, blunted to '-50mmHg' and '-46mmHg' with 10 mmHg compression before rising; maximal tolerable compression 'did not provide additional benefit'.…the full check Abstract only. — source: research lane, from dossier neurogenic-orthostatic-hypotension §5 (2026-09-28) — primary source: PMID 25448247 — evidence class 2 (published finding); not independently checked — needs a cold re-retrieval of the cited source by someone who did not draft this; Verifier 2026-09-28: literature-detail 25448247 → found, PubMed PMID=25448247 (efetch), https://pubmed.ncbi.nlm.nih.gov/25448247/
A 2017 systematic review grading nOH treatments by GRADE states a strong recommendation for use of abdominal binders among non-pharmacological measures, and that midodrine and droxidopa reach a strong recommendation level for pharmacological treatment.
jurisdiction: US — confidence: verified — note: cold re-retrieval; verbatim: 'systematic review ... according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE)', 'strong recommendation for use of abdominal binders', 'midodrine and droxidopa reach a strong recommendation level'. Published…the full check 2017 in J Neural Transm; the abstract does not identify it as a US society guideline. Abstract only. — source: research lane, from dossier neurogenic-orthostatic-hypotension §4 (2026-09-28) — primary source: PMID 29058089 — evidence class 2 (published finding); not independently checked — needs a cold re-retrieval of the cited source by someone who did not draft this; Verifier 2026-09-28: literature-detail 29058089 → found, PubMed PMID=29058089 (efetch), https://pubmed.ncbi.nlm.nih.gov/29058089/
The EFNS guidelines on the diagnosis and management of orthostatic hypotension (2006) list elastic abdominal binders and stockings among physical measures in initial management, with midodrine and dihydroxyphenylserine among second-line drugs.
jurisdiction: US — confidence: verified — note: cold re-retrieval; matches: 'The management initially consists of education ... Physical measures include leg crossing, squatting, elastic abdominal binders and stockings'; 'Second line drugs include sympathomimetics, such as midodrine, ephedrine, or…the full check dihydroxyphenylserine'. Jurisdiction caveat: EFNS is a European guideline, so this verifies what the document says, not US practice. Literature search closed March 2005. Abstract only. — source: research lane, from dossier neurogenic-orthostatic-hypotension §4 (2026-09-28) — primary source: PMID 16930356 — evidence class 2 (published finding); not independently checked — needs a cold re-retrieval of the cited source by someone who did not draft this; Verifier 2026-09-28: literature-detail 16930356 → found, PubMed PMID=16930356 (efetch), https://pubmed.ncbi.nlm.nih.gov/16930356/
A US claims-database study estimated the 2021 age-adjusted prevalence of multiple system atrophy at 12.4 per 100,000 (at least one MSA claim, age 30 or older), translating to 41,133 persons in the 2021 US population; requiring two or more claims gave 5.7 per 100,000.
jurisdiction: US — confidence: verified — note: cold re-retrieval; matches: age ≥30, US claims database 2016-2021, primary endpoint '≥1 MSA claim', age-adjusted prevalence '12.4 per 100,000 translating to 41,133 persons in the 2021 US population', ≥2 claims age-adjusted '5.7'. The ≥1-claim definition is the looser…the full check one; at ≥2 claims the count is roughly halved. Abstract only. — source: research lane, from dossier neurogenic-orthostatic-hypotension §1 (2026-09-28) — primary source: PMID 37951144 — evidence class 2 (published finding); not independently checked — needs a cold re-retrieval of the cited source by someone who did not draft this; Verifier 2026-09-28: literature-detail 37951144 → found, PubMed PMID=37951144 (efetch), https://pubmed.ncbi.nlm.nih.gov/37951144/
Combining five North American cohorts, Parkinson disease prevalence among people aged 45 or older was estimated at 572 per 100,000 (95% CI 537-614), about 680,000 US individuals in 2010, with a projection (not a count) of about 930,000 in 2020.
jurisdiction: US — confidence: verified — note: cold re-retrieval; figures match: '572 per 100,000 (95% confidence interval 537-614)' age ≥45, '680,000 individuals in the US aged ≥45 years with PD in 2010', 'approximately 930,000 in 2020' (a Census-based projection, as the claim says). One wording point: five cohort…the full check studies were run, but the pooled estimate used 'meta-estimates from California, Minnesota, and Ontario', which excludes the Hawaii cohort. The authors call these 'minimum estimates'. Abstract only. — source: research lane, from dossier neurogenic-orthostatic-hypotension §1 (2026-09-28) — primary source: PMID 30003140 — evidence class 2 (published finding); not independently checked — needs a cold re-retrieval of the cited source by someone who did not draft this; Verifier 2026-09-28: literature-detail 30003140 → found, PubMed PMID=30003140 (efetch), https://pubmed.ncbi.nlm.nih.gov/30003140/
A meta-analysis of 19 studies (n=4,973 patients with alpha-synucleinopathies) estimated supine hypertension prevalence at 30.4% (95% CI 26.4-34.7), 46.5% in MSA with orthostatic hypotension.
jurisdiction: US — confidence: verified — note: cold re-retrieval; matches: 'Nineteen studies involving 4973 patients', overall SH '30.4% (95% CI: 26.4-34.7; I2 = 87.6%)', MSA with OH '46.5%'. Heterogeneity is high (I²=87.6%). Abstract only. — source: research lane, from dossier neurogenic-orthostatic-hypotension §1…the full check (2026-09-28) — primary source: PMID 40406920 — evidence class 2 (published finding); not independently checked — needs a cold re-retrieval of the cited source by someone who did not draft this; Verifier 2026-09-28: literature-detail 40406920 → found, PubMed PMID=40406920 (efetch), https://pubmed.ncbi.nlm.nih.gov/40406920/
In MarketScan Commercial and Medicare Supplemental claims (2009-2013), patients with probable Parkinson disease plus nOH (n=281) had a mean age of 77 years versus 74 for Parkinson disease alone (n=17,421), and more often had a medically attended fall after index (30% vs 21%).
jurisdiction: US — confidence: verified — note: cold re-retrieval; matches: MarketScan Commercial and Medicare Supplemental 2009-2013, PD n=17,421 and PD+nOH n=281, mean age '77 vs 74 years', post-index medically attended fall '30% vs 21%'. nOH is identified by proxy ('There is no ICD-9-CM diagnosis code for nOH'),…the full check and the Medicare Supplemental population excludes FFS-only beneficiaries. Abstract only. — source: research lane, from dossier neurogenic-orthostatic-hypotension §1 (2026-09-28) — primary source: PMID 28125950 — evidence class 2 (published finding); not independently checked — needs a cold re-retrieval of the cited source by someone who did not draft this; Verifier 2026-09-28: literature-detail 28125950 → found, PubMed PMID=28125950 (efetch), https://pubmed.ncbi.nlm.nih.gov/28125950/
Among 732 consecutive Chinese multiple system atrophy patients, 15.6% had camptocormia, 4.2% Pisa syndrome and 3.3% antecollis, with postural deformity associated with the parkinsonian (MSA-P) subtype and disease severity.
jurisdiction: US — confidence: verified — note: cold re-retrieval; matches: 732 consecutive Chinese MSA patients, camptocormia 15.6%, Pisa 4.2%, antecollis 3.3%, associated with MSA-P (OR 3.870) and total UMSARS. Jurisdiction caveat: a Chinese cohort under a US tag, verified as what the paper reports, not as US…the full check prevalence. Abstract only. — source: research lane, from dossier neurogenic-orthostatic-hypotension §7 (2026-09-28) — primary source: PMID 30987897 — evidence class 2 (published finding); not independently checked — needs a cold re-retrieval of the cited source by someone who did not draft this; Verifier 2026-09-28: literature-detail 30987897 → found, PubMed PMID=30987897 (efetch), https://pubmed.ncbi.nlm.nih.gov/30987897/
A method using three body-fixed inertial sensors (trunk sensor for lying) reported high sensitivity and specificity for detecting sitting, standing, lying and walking in 10 Parkinson disease patients treated with STN-DBS and 10 controls against video; the abstract gives no numeric accuracy figures.
jurisdiction: US — confidence: verified — note: cold re-retrieval; matches: 'three body-fixed inertial sensors', 'lying periods were detected using a sensor on trunk', ten STN-DBS PD patients and ten controls against video, 'high sensitivity and specificity' for sitting, standing, lying and walking, with no numeric…the full check figure in the abstract, as the claim says. Walking detection used shank sensors, and the setup is not a single torso sensor. Abstract only. — source: research lane, from dossier neurogenic-orthostatic-hypotension §7 (2026-09-28) — primary source: PMID 18075046 — evidence class 2 (published finding); not independently checked — needs a cold re-retrieval of the cited source by someone who did not draft this; Verifier 2026-09-28: literature-detail 18075046 → found, PubMed PMID=18075046 (efetch), https://pubmed.ncbi.nlm.nih.gov/18075046/
A motor-driven active abdominal binder that applies compression upon detection of standing was tested in 20 healthy volunteers aged 18-50, achieving mean compression of about 11 mmHg (SD about 1) versus about 8 mmHg (SD about 3) for a commercial passive binder.
jurisdiction: US — confidence: verified — note: cold re-retrieval; matches: 'motor-driven abdominal compression upon the detection of standing', twenty healthy volunteers aged 18-50, active '≈ 11 mmHg' (SD ≈ 1) versus passive '≈ 8 mmHg; SD ≈ 3'. Healthy volunteers only, at about a quarter of the 40 mmHg set pressure…the full check in the file's mechanism. This is the nearest published posture-triggered analog, and it is an adjacent-art signal (Annals of Biomedical Engineering 2026). Abstract only. — source: research lane, from dossier neurogenic-orthostatic-hypotension §7 (2026-09-28) — primary source: PMID 41483109 — evidence class 2 (published finding); not independently checked — needs a cold re-retrieval of the cited source by someone who did not draft this; Verifier 2026-09-28: literature-detail 41483109 → found, PubMed PMID=41483109 (efetch), https://pubmed.ncbi.nlm.nih.gov/41483109/
In the ampreloxetine program, both the SEQUOIA and REDWOOD phase 3 trials in symptomatic nOH did not meet their primary endpoints; a prespecified MSA subgroup (n=73 entered) showed symptom maintenance on drug versus worsening on placebo in secondary endpoints.
jurisdiction: US — confidence: verified — note: cold re-retrieval; verbatim: 'Both SEQUOIA and REDWOOD did not meet their primary endpoints'; 'Seventy-three patients with MSA entered the program'; prespecified MSA subgroup, 'at week 6 of RW, symptoms remained stable in the ampreloxetine group, but worsened on placebo'…the full check (OHSA composite difference -1.6, p=0.0056). The primary treatment-failure difference in the subgroup was not significant (40% vs 15%, p=0.11), and the authors grade it Class III. Abstract only. — source: research lane, from dossier neurogenic-orthostatic-hypotension §7 (2026-09-28) — primary source: PMID 42475649 — evidence class 2 (published finding); not independently checked — needs a cold re-retrieval of the cited source by someone who did not draft this; Verifier 2026-09-28: literature-detail 42475649 → found, PubMed PMID=42475649 (efetch), https://pubmed.ncbi.nlm.nih.gov/42475649/
No patent in the INPADOC family of US publication US2015313608 ('Compression device, system, and method for decreasing abdominal venous pooling', filed 2013-11-04) has issued as a granted US patent that is currently in force.
jurisdiction: US — confidence: unconfirmed — note: the patent connector answers bibliographic dates only: it returned verified for the publication's existence (title matches, filed 2013-11-04, naive 20-year expiry 2033-11-04), which is not the claim. Whether any family member issued as a US grant and whether it is in…the full check force (maintenance fees, terminal disclaimers, abandonment) is an INPADOC-family and USPTO (United States Patent and Trademark Office) legal-status question no connector in this repo answers this; needs a human-run family and status search. A naive expiry in the future says nothing either way about grant — source: condition C4 from the legal-ip position (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: patent US2015313608 --jurisdiction US → verified (existence and dates only, not the claim), EPO OPS published-data/publication epodoc=US2015313608
Outside the US2015313608 family, no live US patent or pending US published application claims automatic posture-sensor-triggered inflation of an abdominal or truncal compression bladder, or closed-loop pressure control of such a bladder, for treating orthostatic hypotension.
jurisdiction: US — confidence: unconfirmed — note: freedom-to-operate absence claim across all live US patents and published applications; no connector in this repo answers this (patent looks up one known ID, it does not search claims). Needs a human-commissioned FTO search — source: condition C4 from the legal-ip…the full check position (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: no invocation possible — no claim-search connector
US publication US2015313608 discloses activating an inflatable abdominal compression device in response to a sensed change of the wearer to an upright posture.
jurisdiction: US — confidence: unconfirmed — note: a claim about what the publication discloses; the patent connector returns title and dates, never the specification or claims text, so the disclosure is unread. Title only: 'Compression device, system, and method for decreasing abdominal venous pooling' — source:…the full check condition C4 from the legal-ip position (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: patent US2015313608 --jurisdiction US → verified (existence and dates only), EPO OPS published-data/publication epodoc=US2015313608
openFDA lists 15 510(k) clearances under product code JOW (compressible limb sleeve) with decision dates from 2024-09-28 to 2026-09-28, from 14 distinct applicants.
jurisdiction: US — confidence: unconfirmed — note: the numbers match: a clearances window scan returns 15 JOW 510(k)s decided 2024-10-04 to 2026-09-11 (total_matches 15, not truncated), from 14 distinct applicants (Bio Compression Systems holds two: K261807, K250974). But a window scan is a ScanResult that cannot…the full check carry a tag and there is no point connector for a count, so this stays unconfirmed. Scan-supported, not verified — source: condition C4 from the legal-ip position (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: no tag-bearing invocation — scan only (clearances --product-code JOW --since 2024-09-28 --until 2026-09-28, found, 15)
The device described in idea-019's mechanism is a system of at least three separately manufactured objects with different service lives: a reusable powered controller (pump, vent valve, pressure sensor, posture sensor, rechargeable battery and firmware), a single-patient multi-use inflatable bladder-and-garment worn daily against the torso, and a charger. Its per-patient cost of goods is therefore the controller plus the garments consumed over the controller's service life, not a single unit price. The nearest cleared analog architecture, the Kendall SCD SmartFlow system (K230028), is likewise described in its 510(k) summary as a controller and tubing with single-patient-use garments purchased separately.
jurisdiction: US — confidence: unconfirmed — note: compound. The design-architecture and cost-of-goods sentences describe this candidate's own design and have no primary source. Verifier re-run 2026-09-29: the K230028 half is verified. Three back-to-back runs of clearance-summary K230028 each retrieved the summary…the full check PDF and returned verified, as did a fourth run with the claim's phrase as --expect-indication. The earlier "no summary PDF found" (HTTP 401/404) was therefore a transient fetch failure, not an absent summary. Verbatim from the summary: "The system consists of the controller, the tubing assemblies (provided with the controller) and single-patient use garments (purchased separately from this controller)." Caveat for anyone using it as an analog: the same text states the system is "intended for use in a clinical setting by health care professionals" and compresses the limbs ("leg sleeves and foot cuffs") for DVT/PE prophylaxis. It is not a home-use, abdominal or OH-indicated device. It supports the architecture analogy only, not a predicate or indication argument. Tag stays unconfirmed because the design-architecture and cost-of-goods sentences describe this candidate's own design and no primary source can reach them. — source: condition C1 from the operations-npi position (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29 (earlier run): clearance-summary K230028 --jurisdiction US → unconfirmed: no 510(k) summary PDF found (superseded); Verifier 2026-09-29 (re-run): clearance-summary K230028 --jurisdiction US ×3 → verified, and clearance-summary K230028 --expect-indication "single-patient use garments (purchased separately from this controller)" --jurisdiction US → verified, source_ref "FDA 510(k) summary K230028 (https://www.accessdata.fda.gov/cdrh_docs/pdf23/K230028.pdf)"
Under FDA's guidance on the use of ISO 10993-1, idea-019's garment is a surface device contacting intact skin with a cumulative contact duration over 30 days (the permanent-contact category), for which the biocompatibility endpoints to be addressed include cytotoxicity, sensitization and irritation, evaluated on the final finished device; for a single-patient multi-use garment that means test articles conditioned through the labelled cleaning or laundering regimen, so the cleaning regimen must be fixed as a design input before biocompatibility testing.
jurisdiction: US — confidence: unconfirmed — note: a claim about what FDA's ISO 10993-1 guidance requires. FDA guidance documents are outside every connector's reach (regulation serves CFR text only); no connector in this repo answers this. The cleaning-regimen-as-design-input sentence is an engineering inference, not…the full check a source statement — source: condition C2 from the operations-npi position (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: no invocation possible — FDA guidance not reachable
A home-use, battery-powered, software-controlled compression controller of the kind idea-019 describes would be expected to show conformance to IEC 60601-1 (basic safety and essential performance), IEC 60601-1-2 (electromagnetic compatibility), IEC 60601-1-11 (home healthcare environment), IEC 62304 (software life cycle) and IEC 62133-2 (lithium battery safety), each of which is listed in FDA's Recognized Consensus Standards database.
jurisdiction: US — confidence: unconfirmed — note: whether each standard is listed in FDA's Recognized Consensus Standards database, and what FDA would expect, is no connector in this repo answers this (no recognized-standards connector; not CFR text) — source: condition C3 from the operations-npi position…the full check (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: no invocation possible — no recognized-standards connector
openFDA device recalls for product code JOW initiated between 2021-09-28 and 2026-09-28 number four: Z-1917-2025, Z-1918-2025 and Z-1919-2025 (Cardinal Health Kendall SCD sleeves, FDA root cause 'Software change control', related 510(k) K230028) and Z-1612-2023 (Stryker Sustainability Solutions reprocessed DVT compression sleeves, possible mislabeling or mispackaging, root cause under investigation by firm); openFDA returns no recall for product code LHX in the same window.
jurisdiction: US — confidence: unconfirmed — note: the records match: a recalls window scan of JOW 2021-09-28 to 2026-09-28 returns exactly four (total_matches 4, not truncated) — Z-1917/1918/1919-2025 (Cardinal Health 200, LLC, root cause 'Software change control', related 510(k) K230028) and Z-1612-2023 (Stryker…the full check Sustainability Solutions, reprocessed DVT compression sleeves 'may be mislabeled and/or mispackaged', root cause 'Under Investigation by firm', related 510(k) K100909); the same scan for LHX returns none. A window scan is a ScanResult that cannot carry a tag and there is no recall point connector, so this stays unconfirmed. Scan-supported, not verified — source: condition C4 from the operations-npi position (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: no tag-bearing invocation — scan only (recalls --product-code JOW --since 2021-09-28 --until 2026-09-28, found, 4; recalls --product-code LHX same window, none)
At the annual production volume idea-019's business case assumes, the fully loaded cost of goods of one patient's system (controller plus the garments consumed over the controller's service life) is below the Medicare purchase allowable of the E0650-E0652 pneumatic-compressor family code under which the device would bill, and it remains below that allowable at one tenth of that volume.
jurisdiction: US — confidence: unconfirmed — note: a cost-of-goods versus allowable comparison. The COGS (cost of goods sold) side is this candidate's own unbuilt cost model and has no primary source. The allowable side is unchecked too: payment has no DMEPOS fee schedule cached (data/hcpcs_payment_rates.csv absent; CLFS (clinical laboratory fee schedule) only per…the full check data/README.md) — source: condition C6 from the operations-npi position (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: payment E0650 --jurisdiction US → unconfirmed: no local cache at data/hcpcs_payment_rates.csv; Verifier 2026-09-29 re-check, tag holds at unconfirmed: payment E0650 --jurisdiction US → verified, local cache of CMS DMEPOS fee schedule, code=E0650, modifier=NU+RR+UE, schedule=DMEPOS, release=July 2026; payment E0651 --jurisdiction US → verified (same, E0651); payment E0652 --jurisdiction US → verified (same, E0652). The allowable half is now on record: NU (new purchase) non-rural allowables E0650 $872.43-$1,026.39, E0651 $1,112.52-$1,308.85, E0652 $6,422.01-$7,555.31 across contiguous states/DC (allowed amounts, coinsurance comes out of them; category IN for all three). The COGS half has no primary source, so the comparison the claim makes still cannot be checked, and which code the device would bill under is itself unsettled (a factor of ~7 between E0650 and E0652).
The miniature air pump, vent valve and gauge pressure sensor an idea-019 controller requires are catalogue components each available from at least two independent suppliers, so the controller's bill of materials carries no single-source electromechanical component.
jurisdiction: US — confidence: unconfirmed — note: a supply-chain claim; no connector in this repo answers this. Needs supplier quotes or a sourcing study — source: condition C7 from the operations-npi position (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29:…the full check no invocation possible — no supply-chain connector
The Vanderbilt randomized, double-blind, sham-controlled study NCT03482297 (automated abdominal binder at about 40 mmHg versus a 5 mmHg sham binder, 28 enrolled, multiple system atrophy and pure autonomic failure, COMPLETED) has results, posted to ClinicalTrials.gov or published in a peer-reviewed journal, showing improvement on at least one of its primary outcomes (orthostatic tolerance after 10 minutes of standing, or Orthostatic Hypotension Symptom Assessment score) with the active binder versus sham.
jurisdiction: US — confidence: unconfirmed — note: no results found. ClinicalTrials.gov record NCT03482297 reads status=COMPLETED, enrollment 28 actual, randomized parallel double-masked, primary outcomes orthostatic tolerance and OHSA at 10 minutes standing, and hasResults=false — NO results posted. A PubMed scan for…the full check 'NCT03482297' since 2018 returns no record. That leaves the peer-reviewed half open rather than refuted (a scan miss is not an absence and the claim is disjunctive), but nothing supports the claim. Scan records only — source: condition C6 from the clinical position (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: no tag-bearing invocation — scan only (trial-detail NCT03482297, found, hasResults=false; literature "NCT03482297" --since 2018-01-01, none)
In a single-arm home-use feasibility study of at least 20 adults with symptomatic neurogenic orthostatic hypotension due to primary autonomic failure, using a posture-triggered servo-controlled abdominal compression device for at least 4 weeks, device-logged compression is active for the majority of device-detected upright time, and fewer than one in five participants discontinue for abdominal discomfort, breathlessness, reflux or skin injury.
jurisdiction: US — confidence: unconfirmed — note: a claim about the result of a feasibility study that has not been run; no primary source can exist yet, and no connector in this repo answers this — source: condition C6 from the clinical position (2026-09-28) — stated by a chair, never checked; recorded so the…the full check Verifier can see it; Verifier 2026-09-29: no invocation possible — study not yet conducted
A randomized, double-blind, parallel-group study in adults with symptomatic neurogenic orthostatic hypotension due to Parkinson disease, multiple system atrophy or pure autonomic failure, comparing a posture-triggered servo-controlled abdominal compression device at a therapeutic set pressure against the same device inflating to a sub-therapeutic sham pressure (about 5 mmHg) over 12 weeks of home use, shows a pre-specified improvement in Orthostatic Hypotension Questionnaire composite score versus sham at 12 weeks at least as large as the 0.90-unit difference the droxidopa pivotal reported at 7 days, with no increase in supine systolic blood pressure versus sham.
jurisdiction: US — confidence: unconfirmed — note: a claim about the result of a pivotal study that has not been run; no primary source can exist yet, and no connector in this repo answers this. The 0.90-unit droxidopa comparator was not re-checked in this pass — source: condition C6 from the clinical position…the full check (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: no invocation possible — study not yet conducted
The symptom benefit of servo-controlled abdominal compression in neurogenic orthostatic hypotension is present in patients with Parkinson disease, not only in multiple system atrophy and pure autonomic failure, as shown by a pre-specified Parkinson disease stratum of a randomized sham-controlled study with an effect on Orthostatic Hypotension Questionnaire composite in the same direction and of comparable size to the whole cohort.
jurisdiction: US — confidence: unconfirmed — note: a claim about a Parkinson-disease stratum of a study that has not been run; no primary source can exist yet. Noted: NCT03482297 enrolled MSA and PAF (pure autonomic failure) only, so it cannot supply this — source: condition C6 from the clinical position (2026-09-28) — stated by a chair,…the full check never checked; recorded so the Verifier can see it; Verifier 2026-09-29: no invocation possible — study not yet conducted
FDA would classify a powered, posture-triggered, servo-controlled abdominal compression device carrying this file's intended use (home prescription use to reduce orthostatic symptom burden and increase upright standing time in symptomatic nOH due to primary autonomic failure) into Class II through the De Novo pathway, with general and special controls, rather than into Class III requiring premarket approval.
jurisdiction: US — confidence: unconfirmed — note: checked against intended_use as written in frontmatter (home prescription use, adults with symptomatic nOH due to primary autonomic failure, posture-triggered servo-controlled abdominal compression, to reduce orthostatic symptom burden and increase upright standing…the full check time). A prediction of an FDA classification decision; no connector answers what FDA would decide. Context only, not evidence: the cached De Novo listing (494 records) has no grant matching 'abdominal binder', 'abdominal compression' or 'orthostatic hypotension', so no existing De Novo regulation already covers this intended use — source: condition C1 from the regulatory position (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: no invocation answers the claim; context denovo "abdominal compression" --jurisdiction US → refuted (no match — about the De Novo listing only), local cache of FDA De Novo listing
None of the 510(k) clearances under 21 CFR 870.5800 for pneumatic anti-shock trousers (product code LHX: K812564, K841605, K874774, K953763; product code JOW: K873997, K904267) carries an indication for the treatment of orthostatic hypotension or for home use, so none is a predicate carrying this file's intended use.
jurisdiction: US — confidence: unconfirmed — note: checked against intended_use as written in frontmatter (home prescription use, adults with symptomatic nOH due to primary autonomic failure, posture-triggered servo-controlled abdominal compression, to reduce orthostatic symptom burden and increase upright standing…the full check time). Every one of the six summaries is unreadable: clearance-summary found no posted 510(k) summary PDF for K812564, K841605, K874774, K953763, K873997 or K904267 (pre-1996 clearances; HTTP 401/404). An absent summary says nothing about the cleared indication, so the absence of an OH or home-use indication cannot be recorded. Product codes do check out: LHX is 'Trousers, Anti-Shock' and JOW 'Sleeve, Limb, Compressible', both 870.5800 Class II — source: condition C2 from the regulatory position (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: clearance-summary K812564 --expect-indication "orthostatic" --jurisdiction US → unconfirmed: no 510(k) summary PDF found (same for K841605, K874774, K953763, K873997, K904267); classification --product-code LHX --jurisdiction US → verified, openFDA device/classification product_code=LHX
510(k) K153311 (Tactile Systems Flexitouch System, product code PPS, 21 CFR 870.5800, decided 2016-09-14) has an Indications for Use statement that names garments for the trunk and chest, so FDA has cleared non-limb, truncal pneumatic compression garments by 510(k) within the 870.5800 family; none of the listed indications is orthostatic hypotension.
jurisdiction: US — confidence: verified — note: checked against intended_use as written in frontmatter (home prescription use, adults with symptomatic nOH due to primary autonomic failure, posture-triggered servo-controlled abdominal compression, to reduce orthostatic symptom burden and increase upright standing…the full check time); the finding is that K153311 is NOT a predicate carrying it. All parts resolve: openFDA records K153311 Flexitouch System, Tactile Systems Technology, decided 2016-09-14; product code PPS is Class II under 870.5800 ('Sleeve, Head And Neck, Compressible'); the summary IFU (instructions for use) reads verbatim 'The Flexitouch system and garments for legs, arms, trunk, and chest are intended for use ... for the treatment of many conditions such as: Lymphedema, Primary lymphedema, Post mastectomy edema, Edema following trauma and sports injuries, Post immobilization edema, Venous insufficiencies, Reducing wound healing time, ... stasis dermatitis, venous stasis ulcers, or arterial and diabetic leg ulcers', plus head and neck lymphedema. No orthostatic indication. Caveat: 'such as' makes the list non-exhaustive, and 'trunk' is not 'abdomen' — whether a truncal lymphedema garment supports an abdominal OH device is an SE judgment this does not settle — source: condition C3 from the regulatory position (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: clearance-summary K153311 --expect-indication "trunk" --jurisdiction US → verified, FDA 510(k) summary K153311 (https://www.accessdata.fda.gov/cdrh_docs/pdf15/K153311.pdf); 510k "Flexitouch" --applicant "Tactile" --jurisdiction US → verified, openFDA device/510k k_number=K153311; classification --product-code PPS --jurisdiction US → verified, openFDA device/classification product_code=PPS
21 CFR 890.5650 identifies a powered inflatable tube massager as a powered device using an inflatable pressure cuff intended for medical purposes such as to increase circulation, classified Class II, and openFDA lists product code IRP under it with 510(k) required; a powered inflatable abdominal garment stripped of any orthostatic-hypotension claim would therefore fall under a Class II 510(k) regulation (890.5650 or 870.5800) rather than under the Class I exempt truncal-orthosis regulation 21 CFR 890.3490.
jurisdiction: US — confidence: unconfirmed — note: checked against a stripped indication (no orthostatic claim), not the frontmatter intended_use. The text halves verify: eCFR 890.5650 reads 'a powered device intended for medical purposes, such as to relieve minor muscle aches and pains and to increase circulation ...…the full check by use of an inflatable pressure cuff. (b) Classification. Class II (performance standards)'; openFDA lists IRP 'Massager, Powered Inflatable Tube' Class 2 under 890.5650; 890.3490 is Class I and 510(k)-exempt and names 'Abdominal' orthoses — for support or immobilization of fractures, strains or sprains. Two parts do not resolve: the classification record carries no submission-type field, so 'with 510(k) required' is unchecked; and 'would therefore fall under' is an FDA classification judgment the regulation text does not settle — source: condition C6 from the regulatory position (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: regulation 890.5650 --expect "inflatable pressure cuff" --jurisdiction US → verified, eCFR versioner title-21, issue 2026-09-25, section=890.5650; classification --product-code IRP --jurisdiction US → verified, openFDA device/classification product_code=IRP; regulation 890.3490 --expect "Class I" --jurisdiction US → verified, eCFR versioner title-21, issue 2026-09-25, section=890.3490
FDA would accept, as the clinical data for a De Novo carrying an orthostatic symptom-burden and upright-standing-time claim for this device, a randomized sham-controlled study in primary autonomic failure of the design registered as NCT03482297 (about 40 mmHg active versus about 5 mmHg sham), provided the device is tested in its posture-triggered mode over home use rather than manually activated for single study-day sessions.
jurisdiction: US — confidence: unconfirmed — note: checked against intended_use as written in frontmatter (home prescription use, adults with symptomatic nOH due to primary autonomic failure, posture-triggered servo-controlled abdominal compression, to reduce orthostatic symptom burden and increase upright standing…the full check time). A prediction of what clinical data FDA would accept for a De Novo; that is an FDA review judgment (pre-submission territory) and no connector in this repo answers this — source: condition C7 from the regulatory position (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: no invocation possible — FDA review judgment
The CMS DMEPOS fee schedule in force for 2026 publishes a Medicare fee-schedule allowable for each of HCPCS E0650, E0651 and E0652 (pneumatic compressor, home model) and for HCPCS E0656 (segmental pneumatic appliance, trunk).
jurisdiction: US — confidence: verified — note: Verifier 2026-09-29 re-check: the July 2026 CMS DMEPOS fee schedule (now cached) publishes an allowable for each of the four codes: E0650, E0651, E0652 on NU, RR and UE lines (category IN), E0656 on an RR line only (category CR, $82.35 non-rural). Earlier note…the full check (superseded): the codes exist (hcpcs verified E0650, E0651, E0652, E0656 in the October 2026 Level II file), but whether the 2026 DMEPOS fee schedule publishes an allowable for each is unchecked: payment has no DMEPOS fee schedule cached (data/hcpcs_payment_rates.csv absent). Missing-file gap, not an absence — source: condition C2 from the commercial position (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: payment E0650 --jurisdiction US → unconfirmed: no local cache at data/hcpcs_payment_rates.csv (same for E0651, E0652, E0656); Verifier 2026-09-29 re-check: payment E0650 --jurisdiction US → verified, local cache of CMS DMEPOS fee schedule, code=E0650, modifier=NU+RR+UE, schedule=DMEPOS, release=July 2026; payment E0651 --jurisdiction US → verified, local cache of CMS DMEPOS fee schedule, code=E0651, modifier=NU+RR+UE, schedule=DMEPOS, release=July 2026; payment E0652 --jurisdiction US → verified, local cache of CMS DMEPOS fee schedule, code=E0652, modifier=NU+RR+UE, schedule=DMEPOS, release=July 2026; payment E0656 --jurisdiction US → verified, local cache of CMS DMEPOS fee schedule, code=E0656, modifier=RR, schedule=DMEPOS, release=July 2026
A posture classifier running on a single torso-worn inertial sensor, validated against video in a home-like setting in adults with Parkinson disease, multiple system atrophy or pure autonomic failure that includes patients with camptocormia and with dyskinesia, classifies a recumbent wearer as upright in fewer than 1 in 1,000 recumbent periods, and no such false-upright classification persists for more than 60 seconds.
jurisdiction: US — confidence: unconfirmed — note: an engineering performance claim about a device or bench rig that does not yet exist; no primary source can exist yet, and no connector in this repo answers this. To be satisfied by design verification testing — source: condition C1 from the technology position…the full check (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: no invocation possible — untested design performance
A battery-powered pneumatic unit small enough to be worn under clothing can inflate an abdominal bladder to 90% of a 40 mmHg set pressure within 15 seconds of a detected sit-to-stand transition.
jurisdiction: US — confidence: unconfirmed — note: an engineering performance claim about a device or bench rig that does not yet exist; no primary source can exist yet, and no connector in this repo answers this. To be satisfied by design verification testing — source: condition C2 from the technology position…the full check (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: no invocation possible — untested design performance
A bench rig demonstrates that the device vents its abdominal bladder to below 5 mmHg within 10 seconds under each single fault (pump runaway, pressure-sensor failure, loss of the posture signal, controller or firmware lock-up) through a normally-open de-energise-to-vent valve and an independent mechanical pressure-relief valve that do not depend on the servo firmware.
jurisdiction: US — confidence: unconfirmed — note: an engineering performance claim about a device or bench rig that does not yet exist; no primary source can exist yet, and no connector in this repo answers this. To be satisfied by design verification testing — source: condition C3 from the technology position…the full check (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: no invocation possible — untested design performance
An independent recumbency interlock, a second posture-sensing channel with its own firmware path separate from the primary classifier, vents the abdominal bladder within 60 seconds of the wearer becoming recumbent in every case where the primary classifier has failed to, bounding supine pressure exposure per false-inflation event at 60 seconds.
jurisdiction: US — confidence: unconfirmed — note: an engineering performance claim about a device or bench rig that does not yet exist; no primary source can exist yet, and no connector in this repo answers this. To be satisfied by design verification testing — source: condition C4 from the technology position…the full check (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: no invocation possible — untested design performance
In no more than three stock garment sizes, the skin-interface pressure measured over the splanchnic region stays within 5 mmHg of the bladder set pressure across the waist-circumference range of adults with primary autonomic failure.
jurisdiction: US — confidence: unconfirmed — note: an engineering performance claim about a device or bench rig that does not yet exist; no primary source can exist yet, and no connector in this repo answers this. To be satisfied by design verification testing — source: condition C5 from the technology position…the full check (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: no invocation possible — untested design performance
The posture classifier's upright-versus-recumbent decision does not change when the co-located abdominal bladder inflates to 40 mmHg or vents to zero, or when the garment and sensor housing migrate on the torso over a day of wear.
jurisdiction: US — confidence: unconfirmed — note: an engineering performance claim about a device or bench rig that does not yet exist; no primary source can exist yet, and no connector in this repo answers this. To be satisfied by design verification testing — source: condition C6 from the technology position…the full check (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: no invocation possible — untested design performance
A wearable unit powered by a battery of 20 Wh or less sustains a 16-hour waking day of posture-triggered operation, including at least 60 inflate-and-vent cycles and continuous servo holding at 40 mmHg during upright periods, without recharge.
jurisdiction: US — confidence: unconfirmed — note: an engineering performance claim about a device or bench rig that does not yet exist; no primary source can exist yet, and no connector in this repo answers this. To be satisfied by design verification testing — source: condition C7 from the technology position…the full check (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: no invocation possible — untested design performance
In the October 2026 CMS HCPCS Level II file, E0650 is described as 'Pneumatic compressor, non-segmental home model', E0656 as 'Segmental pneumatic appliance for use with pneumatic compressor, trunk' and E0657 as the same for chest, and every non-segmental pneumatic appliance code (E0655, E0660, E0665, E0666) describes a limb appliance (half arm, full leg, full arm, half leg); no existing Level II descriptor in the E0650-E0676 range names an abdominal appliance or a posture-triggered, sustained-pressure compression device, so billing this device under the existing family requires CMS to accept a descriptor mismatch or to issue a new code.
jurisdiction: US — confidence: unconfirmed — note: descriptor half verified, conclusion not. Every descriptor quoted matches the October 2026 Level II file (E0650 'Pneumatic compressor, non-segmental home model'; E0656 '... trunk'; E0657 '... chest'; E0655 half arm, E0660 full leg, E0665 full arm, E0666 half leg). No…the full check existing code in E0650-E0676 names 'abdominal' or a posture-triggered or sustained-pressure device; the nearest are E0656 trunk, E0670 'integrated, 2 full legs and trunk', E0658 '2 full arms and chest', E0659 'head, neck and chest' (E0653, E0654, E0661-E0664, E0674 do not exist). The conclusion 'requires CMS to accept a descriptor mismatch or to issue a new code' is a coding determination (PDAC (Pricing, Data Analysis and Coding contractor) coding verification) no connector answers, and it omits a third route: E1399 'Durable medical equipment, miscellaneous' exists in the same file — source: condition C1 from the market-access position (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: hcpcs E0650 --jurisdiction US → verified, local cache of CMS HCPCS Level II file, code=E0650 (likewise E0651, E0652, E0655-E0660, E0665-E0673, E0675, E0676 verified; E0653, E0654, E0661-E0664, E0674 not in file); hcpcs E1399 --jurisdiction US → verified
NCD 280.6 (Pneumatic Compression Devices) describes the devices it governs as 'an inflatable garment for the arm or leg' whose garment 'is intermittently inflated and deflated with cycle times', and its text does not describe a garment applied to the abdomen or held at sustained pressure while upright; by its own device description NCD 280.6 does not reach a posture-triggered, sustained-pressure abdominal compression device.
jurisdiction: US — confidence: verified — note: the tag covers the device description and what the text does and does not say, read over the full section body. Verbatim: 'Pneumatic compression devices consist of an inflatable garment for the arm or leg and an electrical pneumatic pump ... The garment is intermittently…the full check inflated and deflated with cycle times and pressures that vary between devices.' Phrase checks over the full text miss 'abdom', 'trunk', 'sustained', 'upright', 'orthostatic', 'splanchnic' and 'continuous' (the connector reports a miss as unconfirmed; here the miss is the finding). The claim limits its conclusion to 'by its own device description'. Whether CMS or a DME MAC would treat the device as outside 280.6 is a separate coverage judgment this does not settle — source: condition C2 from the market-access position (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: ncd 280.6 --expect "inflatable garment for the arm or leg" --jurisdiction US → verified, CMS Pub. 100-3 Medicare NCD Manual, chapter 1 part 4 (Rev. 13808, issued 05-29-26), section=280.6; ncd 280.6 --expect "abdom" --jurisdiction US → unconfirmed (phrase absent — supports the claim)
In the CMS DMEPOS fee schedule, HCPCS E0650, E0651 and E0652 are assigned the capped-rental payment category (paid under 42 CFR 414.229 as monthly rental for up to 13 continuous months, after which title transfers to the beneficiary), not the inexpensive-or-routinely-purchased category, so a device paid within that family is paid as a monthly rental stream rather than a one-time purchase allowable.
jurisdiction: US — confidence: refuted — note: REFUTED by the primary source, Verifier 2026-09-29 re-check. The July 2026 CMS DMEPOS fee schedule assigns E0650, E0651 and E0652 payment category IN (inexpensive and other routinely purchased items) on every pricing line (NU, RR, UE), which is the category the claim says…the full check they are not; none is CR. Read from the raw CMS rows in data/dmepos_fee_schedule.csv as well as the connector detail (e.g. "E0650,RR,,D,IN,126.66,107.66,..."), so not a parse artefact. The trunk appliance E0656 and chest E0657 are CR; the compressors are not. The connector status for the lookup is verified (the fees exist); the refutation is the category field it returns set against the claim's own wording, and no connector flag tests category directly. Consequence: a device paid in this family is paid as a purchase (or IN rental), not as a 13-month capped-rental stream. The 42 CFR 414.229 half of the note below stands but no longer applies to these codes. Earlier note (superseded): the load-bearing half, which payment category the DMEPOS fee schedule assigns E0650-E0652, is unchecked: no DMEPOS fee schedule is cached (data/hcpcs_payment_rates.csv absent). The regulation half partly reads: 42 CFR 414.229 is titled 'Other durable medical equipment—capped rental items' and contains 'title to the equipment', but a check for '13 continuous months' misses (unconfirmed; the rental-month wording is past the excerpt and was not read) — source: condition C3 from the market-access position (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: payment E0650 --jurisdiction US → unconfirmed: no local cache at data/hcpcs_payment_rates.csv; regulation 414.229 --title 42 --expect "title to the equipment" --jurisdiction US → verified, eCFR versioner title-42, issue 2026-08-13, section=414.229; Verifier 2026-09-29 re-check: payment E0650 --jurisdiction US → verified, local cache of CMS DMEPOS fee schedule, code=E0650, modifier=NU+RR+UE, schedule=DMEPOS, release=July 2026, category IN on all lines; payment E0651 --jurisdiction US → verified, same, category IN; payment E0652 --jurisdiction US → verified, same, category IN
DME MAC local coverage determination L33829 (a Medicare local coverage determination number) (Pneumatic Compression Devices) is currently in effect, and its coverage criteria for pneumatic compressors and for trunk or chest appliances (E0656, E0657) are limited to lymphedema and chronic venous insufficiency with venous stasis ulcers, with no provision under which orthostatic hypotension is reasonable and necessary.
jurisdiction: US — confidence: unconfirmed — note: the coverage connector is code-keyed and its cache holds MCD Billing & Coding Articles, not DME MAC LCD text. coverage E0650 and coverage E0656 both return refuted ('no policy names this code'), but that is a cache limit — controls E0601/K0001 also refute, and NCD…the full check 280.6 plainly governs these devices — so it is recorded as unconfirmed. No connector pointed to L33829, so its status and criteria were not read — source: condition C4 from the market-access position (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: coverage E0656 --jurisdiction US → refuted (cache limit, treated as unconfirmed), local cache of CMS Medicare Coverage Database (no policy names this code), code=E0656
This candidate's controller (pump, valve, posture sensor and battery unit) is designed to withstand repeated use by successive patients and to an expected life of at least three years, meeting conditions (1) and (2) of the 42 CFR 414.202 definition of durable medical equipment, with the garment and bladder, if shorter-lived, specified as a separately replaceable accessory.
jurisdiction: US — confidence: unconfirmed — note: the design half, that this controller is built for repeated use by successive patients and a life of at least three years, is a design commitment with no primary source yet. The definition half verifies: 42 CFR 414.202 defines DME as equipment that '(1) Can withstand…the full check repeated use. (2) Effective with respect to items classified as DME after January 1, 2012, has an expected life of at least 3 years', plus conditions (3)-(5) — source: condition C5 from the market-access position (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: regulation 414.202 --title 42 --expect "withstand repeated use" --jurisdiction US → verified, eCFR versioner title-42, issue 2026-08-13, section=414.202
42 CFR 422.101(b) requires Medicare Advantage organizations to comply with CMS national coverage determinations and with the general coverage and benefit conditions of Traditional Medicare, including the criteria for whether an item is a benefit available under Traditional Medicare, so the Part B DME benefit-category and NCD outcome for this device governs Medicare Advantage enrollees as well as fee-for-service beneficiaries.
jurisdiction: US — confidence: verified — note: verbatim: an MA (Medicare Advantage) organization must '(b) Comply with— (1) CMS's national coverage determinations; (2) General coverage and benefit conditions included in Traditional Medicare laws, unless superseded by laws applicable to MA plans. This includes criteria for determining…the full check whether an item or service is a benefit available under Traditional Medicare.' The tag covers basic benefits. It does not cover an MA plan's supplemental benefits (not read), and (b)(3) also binds MA plans to local contractor coverage decisions — source: condition C6 from the market-access position (2026-09-28) — stated by a chair, never checked; recorded so the Verifier can see it; Verifier 2026-09-29: regulation 422.101 --title 42 --expect "national coverage determinations" --jurisdiction US → verified, eCFR versioner title-42, issue 2026-08-13, section=422.101; regulation 422.101 --title 42 --expect "whether an item or service is a benefit available under Traditional Medicare" --jurisdiction US → verified
A home-use, posture-triggered, powered abdominal compression device of idea-019's description meets conditions (3) through (5) of the 42 CFR 414.202 definition of durable medical equipment: it is primarily and customarily used to serve a medical purpose, it is generally not useful to an individual in the absence of an illness or injury, and it is appropriate for use in the home.
jurisdiction: US — confidence: unconfirmed — note: benefit-category determination for this device is a CMS judgment, not a lookup. The regulation text confirms the five DME conditions exist exactly as the claim quotes them (3)-(5), but no connector says whether this device meets them; checked against intended_use:…the full check prescription home use, servo-controlled abdominal compression for symptomatic nOH in primary autonomic failure — source: assessment-surfaced proposition (pillar B3Medicare pays for it, 2026-09-29) — the opportunity rests on this and no checkable statement existed for it; never checked; Verifier 2026-09-29: regulation 414.202 --title 42 --expect "generally is not useful to an individual in the absence of an illness or injury" --jurisdiction US → verified, eCFR versioner title-42, issue 2026-08-13, section=414.202 (definition text only, not its application)
Medicare Part B pays separately for replacement inflatable garments or bladders used with a home pneumatic compressor billed in the E0650-E0652 family, rather than treating them as included in the payment for the compressor, both during and after any capped-rental period.
jurisdiction: US — confidence: unconfirmed — note: unresolved, and its premise is partly contradicted: the July 2026 DMEPOS fee schedule assigns E0650, E0651 and E0652 category IN (inexpensive or routinely purchased), not CR, so the 'capped-rental period' this claim assumes does not apply to that family (see claim…the full check 117). The fee schedule does publish separate allowables for pneumatic appliance/garment codes (E0660 full leg, E0667 segmental full leg, both IN; E0656/E0657 trunk/chest, CR), so they are priced as separate lines, but whether a replacement garment is paid separately or bundled with the compressor is a DME MAC policy-article rule, and the cached coverage index does not link L33829 to these codes (see source), so no policy text was read — source: assessment-surfaced proposition (pillar B7It is a business. A stock-sized…, 2026-09-29) — the opportunity rests on this and no checkable statement existed for it; never checked; Verifier 2026-09-29: payment E0660 --jurisdiction US → verified, local cache of CMS DMEPOS fee schedule, code=E0660, modifier=NU+RR+UE, release=July 2026; payment E0667 --jurisdiction US → verified, same schedule, code=E0667; payment E0657 --jurisdiction US → verified, code=E0657, RR, category CR; coverage E0650 --jurisdiction US → unconfirmed: "No local cache at data/medicare_coverage_policies.csv" (superseded, cache landed mid-pass); re-run 2026-09-29: coverage E0650 --jurisdiction US → refuted, local cache of CMS Medicare Coverage Database (no policy names this code), code=E0650 (same for E0651, E0652, E0656, E0660, E0667). Not used as evidence: the cached file has 1,970 rows, only 3 carrying any E-code, and the DME MAC Pneumatic Compression Devices LCD appears only as article A59219 (Response to Comments, related L33829) with a blank codes column, so the miss describes our code linkage, not CMS. Whether garments are separately payable needs L33829 and its policy article read directly; hcpcs E0656 --jurisdiction US → verified, local cache of CMS HCPCS Level II file, code=E0656 ("Segmental pneumatic appliance for use with pneumatic compressor, trunk")
The contribution margin that US sales of this device can generate among patients with symptomatic neurogenic orthostatic hypotension due to primary autonomic failure, at the Medicare allowable and payment cadence that apply to it, covers the fixed cost of the development programme it requires (prototype and bench work, a home feasibility study, a sham-controlled pivotal study, a De Novo request, a HCPCS coding application and a coverage request) before a follower device can be cleared by 510(k) against it.
jurisdiction: US — confidence: unconfirmed — note: a unit-economics claim; the COGS and programme-cost sides have no primary source, and a market claim is unverifiable by design. The allowable side is now readable (claim 107verified) but it is one input of several — source: assessment-surfaced proposition (pillar B7It is a business. A stock-sized…,…the full check 2026-09-29) — the opportunity rests on this and no checkable statement existed for it; never checked; Verifier 2026-09-29: market "contribution margin covers the fixed development cost before a 510(k) follower" → unverifiable: "no free, authoritative, machine-queryable source" (stays unconfirmed permanently absent a human-attached licensed source)
When a third-party DMEPOS supplier furnishes a capped-rental pneumatic compressor to a Medicare beneficiary, the device manufacturer's revenue for that placement is the price the supplier paid to acquire the controller and garments, paid once into the supplier's inventory, and is lower than the total Medicare allowable the supplier collects over the rental period.
jurisdiction: US — confidence: unconfirmed — note: a commercial-arrangement claim; no connector reads supplier acquisition prices or manufacturer revenue. Also note the premise 'capped-rental' is contradicted for E0650-E0652, which the July 2026 DMEPOS fee schedule assigns category IN (claim 117refuted) — source:…the full check business-case assumption (2026-09-29) — never checked; recorded so the Verifier can see it; Verifier 2026-09-29: market "manufacturer revenue per placement is the supplier acquisition price" → unverifiable: "no free, authoritative, machine-queryable source" (stays unconfirmed permanently absent a human-attached licensed source)
Under 42 CFR 424.57 a device manufacturer may itself enroll as an accredited Medicare DMEPOS supplier and bill the DME MAC directly for its own home-use device, so that the manufacturer collects the Medicare allowable rather than a supplier's acquisition price.
jurisdiction: US — confidence: unconfirmed — note: the section exists but its text, as returned, does not contain the word 'manufacturer'; whether a manufacturer may enroll and bill as a DMEPOS supplier is a CMS enrollment reading not settled by the excerpt. Missing phrase, not a refutation — source: business-case…the full check assumption (2026-09-29) — never checked; recorded so the Verifier can see it — evidence class 1 (registry fact); Verifier 2026-09-29: regulation 424.57 --title 42 --expect "manufacturer" --jurisdiction US → unconfirmed: "42 CFR 424.57 exists but its text does NOT contain the phrase 'manufacturer'", eCFR versioner title-42, issue 2026-08-13, section=424.57
Adults with symptomatic neurogenic orthostatic hypotension due to primary autonomic failure, or their families, will pay the full purchase price of a posture-triggered abdominal compression device out of pocket where no Medicare or commercial payment is available for it.
jurisdiction: US — confidence: unconfirmed — note: stakeholder-behaviour claim; no connector answers it and it is not answered from model judgment — source: business-case assumption (2026-09-29) — never checked; recorded so the Verifier can see it — evidence class 3 (stakeholder future); Verifier 2026-09-29: `adoption…the full check "patients or families pay full purchase price out of pocket"` → unverifiable: needs primary research (interviews, survey, published preference study); not answered from model judgment
A powered inflatable abdominal garment labelled and advertised without any orthostatic-hypotension, blood-pressure or symptom claim can be sold to people with neurogenic orthostatic hypotension without FDA treating its posture-triggered design, or its distribution to that population, as establishing an orthostatic-hypotension intended use under 21 CFR 801.4.
jurisdiction: US — confidence: unconfirmed — note: how FDA would treat this is an interpretation question the regulation text does not settle, so not tagged either way. But the text runs AGAINST the claim and should be read before anyone relies on it: 21 CFR 801.4 says intent 'may be shown by such persons'…the full check expressions, the design or composition of the article, or by the circumstances surrounding the distribution of the article', and 'by circumstances in which the article is, with the knowledge of such persons ... offered or used for a purpose for which it is neither labeled nor advertised' (the knowledge-only safe harbour covers devices already cleared/authorized, which this is not). A posture-triggered design distributed to the nOH population is exactly the 'design' and 'circumstances' the text names. Needs a regulatory counsel reading — source: business-case assumption (2026-09-29) — never checked; recorded so the Verifier can see it; Verifier 2026-09-29: regulation 801.4 --expect "circumstances surrounding the distribution" --jurisdiction US → verified, eCFR versioner title-21, issue 2026-09-25, section=801.4 (phrase present; the text cuts against the claim, see note)
Of the fixed costs in this candidate's development programme (prototype and bench work, a home feasibility study, a sham-controlled pivotal study, a De Novo request, a HCPCS coding application and a coverage request), the sham-controlled pivotal study is the largest single item.
jurisdiction: US — confidence: unconfirmed — note: a cost-structure claim about this candidate's own unbuilt budget; no primary source, market claims unverifiable by design — source: business-case assumption (2026-09-29) — never checked; recorded so the Verifier can see it; Verifier 2026-09-29: `market…the full check "sham-controlled pivotal study is the largest fixed cost item"` → unverifiable: "no free, authoritative, machine-queryable source" (stays unconfirmed permanently absent a human-attached licensed source)
A single-patient multi-use inflatable abdominal garment worn during every upright period of the day and cleaned on its labelled regimen reaches the end of its service life in less than twelve months, so each placement consumes more than one garment per year.
jurisdiction: US — confidence: unconfirmed — note: no connector answers a garment service-life claim; this needs bench durability testing of the actual garment. Not checked against any source — source: business-case assumption (2026-09-29) — never checked; recorded so the Verifier can see it; Verifier 2026-09-29: no…the full check check-type connector exists for device service life; nothing run
Among adults with symptomatic neurogenic orthostatic hypotension due to primary autonomic failure who cannot don a powered abdominal compression garment unaided, most have a caregiver available every morning to put it on correctly before their first upright period of the day.
jurisdiction: US — confidence: unconfirmed — note: stakeholder-behaviour claim; no connector answers it and it is not answered from model judgment — source: deck-surfaced assumption (desirability deck, 2026-09-29) — never checked; recorded so the Verifier can see it — evidence class 3 (stakeholder future); Verifier…the full check 2026-09-29: adoption "caregiver available every morning to don the garment" → unverifiable: needs primary research (interviews, survey, published preference study); not answered from model judgment
Adults with symptomatic neurogenic orthostatic hypotension due to primary autonomic failure will wear a powered abdominal compression garment and its controller under everyday clothing outside the home, rather than restricting use to the home because of the garment's visibility, bulk or pump noise.
jurisdiction: US — confidence: unconfirmed — note: stakeholder-behaviour claim; no connector answers it and it is not answered from model judgment — source: deck-surfaced assumption (desirability deck, 2026-09-29) — never checked; recorded so the Verifier can see it — evidence class 3 (stakeholder future); Verifier…the full check 2026-09-29: adoption "patients wear the powered garment outside the home" → unverifiable: needs primary research (interviews, survey, published preference study); not answered from model judgment
Adults with symptomatic neurogenic orthostatic hypotension who have already tried an elastic abdominal binder will prefer a posture-triggered powered abdominal compression device over the elastic binder strongly enough to switch, despite the powered device's charging, weight and cost.
jurisdiction: US — confidence: unconfirmed — note: stakeholder-behaviour claim; no connector answers it and it is not answered from model judgment — source: deck-surfaced assumption (desirability deck, 2026-09-29) — never checked; recorded so the Verifier can see it — evidence class 3 (stakeholder future); Verifier…the full check 2026-09-29: adoption "elastic binder users switch to a powered device" → unverifiable: needs primary research (interviews, survey, published preference study); not answered from model judgment
A published epidemiological study reports a prevalence estimate for pure autonomic failure that can be applied to the US population.
jurisdiction: US — confidence: unconfirmed — note: a published-finding claim with no citation; the only literature connector is a scan (literature), which returns a lead and never a tag. Needs the specific paper named, then a human or a check-type source — source: deck-surfaced assumption (viability deck,…the full check 2026-09-29) — never checked; recorded so the Verifier can see it — evidence class 2 (published finding); Verifier 2026-09-29: no check-type connector for published epidemiology; nothing run
In a summative human-factors validation study, adults with Parkinson disease, multiple system atrophy or pure autonomic failure, or their caregivers, complete the critical tasks of a posture-triggered abdominal compression device — positioning the garment and posture sensor correctly, connecting and charging the controller, and responding to a fault alarm — without use errors that result in compression while recumbent or no compression on standing.
jurisdiction: US — confidence: unconfirmed — note: a claim about the outcome of a study that has not been run; no source can answer it until the summative human-factors study exists — source: deck-surfaced assumption (feasibility deck, 2026-09-29) — never checked; recorded so the Verifier can see it; Verifier…the full check 2026-09-29: no connector; the study does not exist yet
Abdominal compression at a set pressure below 40 mmHg reduces orthostatic symptom burden versus sham in adults with neurogenic orthostatic hypotension due to primary autonomic failure, so the device's set pressure can be lowered for all-day tolerance without losing the symptom effect.
jurisdiction: US — confidence: unconfirmed — note: a clinical-efficacy claim with no named trial; no check-type connector reads trial results (literature/trials are scans and never tag). Needs a sham-controlled study at sub-40 mmHg to be cited — source: deck-surfaced assumption (feasibility deck, 2026-09-29) —…the full check never checked; recorded so the Verifier can see it; Verifier 2026-09-29: no check-type connector for clinical efficacy; nothing run
When a third-party DMEPOS supplier furnishes this device to a Medicare beneficiary as a purchased item under an E0650-E0652 pneumatic-compressor code (payment category IN, inexpensive or routinely purchased), the device manufacturer's revenue for that placement is the price the supplier paid to acquire the controller and garments, paid once, and is lower than the new-purchase (NU) fee-schedule allowable the supplier collects for it.
jurisdiction: US — confidence: unverified — source: business-case assumption (2026-09-29) — never checked; recorded so the Verifier can see it
Under 42 CFR 414.220(b), Medicare pays for an item in the inexpensive-or-routinely-purchased (IN) category either on a rental basis or as a lump-sum purchase based on the fee schedule, and the total of all payments for the item may not exceed the fee schedule amount for its purchase; so an E0650-E0652 placement paid through the rental (RR) line cannot earn more in total than the new-purchase (NU) allowable.
jurisdiction: US — confidence: unverified — source: business-case assumption (2026-09-29) — never checked; recorded so the Verifier can see it — evidence class 1 (registry fact)
Under 42 CFR 414.210(a), Medicare pays for durable medical equipment on the basis of 80 percent of the lesser of the actual charge and the fee schedule amount, so for a covered E0650-E0652 purchase the beneficiary carries the remaining 20 percent of that amount.
jurisdiction: US — confidence: unverified — source: business-case assumption (2026-09-29) — never checked; recorded so the Verifier can see it — evidence class 1 (registry fact)
Under 42 CFR 414.210(f), Medicare does not pay for a replacement of a durable medical equipment item furnished to the same beneficiary before the end of the item's reasonable useful lifetime, which is five years unless CMS sets another, except where the item is lost, stolen or irreparably damaged; so a purchased controller in the E0650-E0652 family is paid at most once per beneficiary per five years in ordinary use.
jurisdiction: US — confidence: unverified — source: business-case assumption (2026-09-29) — never checked; recorded so the Verifier can see it — evidence class 1 (registry fact)
If this device were billed under an existing HCPCS pneumatic-compressor code, the applicable code would be E0650 (pneumatic compressor, non-segmental home model) rather than E0651 or E0652, because a single abdominal bladder is neither segmental nor calibrated-gradient; its Medicare new-purchase (NU) allowable would therefore be the E0650 amount, the lowest of the three family allowables.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (viability deck, 2026-09-29) — never checked; recorded so the Verifier can see it
A published cohort or registry study reports the proportion of US adults with symptomatic neurogenic orthostatic hypotension due to primary autonomic failure who remain symptomatic despite non-pharmacologic measures.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (viability deck, 2026-09-29) — never checked; recorded so the Verifier can see it — evidence class 2 (published finding)
In adults with neurogenic orthostatic hypotension due to primary autonomic failure, the fall in systolic blood pressure after moving from seated or supine to standing, and the onset of orthostatic symptoms, develop over more than 15 seconds, as reported in a published beat-to-beat or tilt time-course study, so an abdominal bladder that reaches 90% of set pressure within 15 seconds of a detected sit-to-stand transition is pressurised before symptom onset.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (feasibility deck, 2026-09-29) — never checked; recorded so the Verifier can see it — evidence class 2 (published finding)
Words on this page47 abbreviation(s) and code(s), with what each stands for — copied from _shared/plain-language.md
21 CFR
Title 21 of the Code of Federal Regulations — the US food-and-drug rulebook; a number after it is one regulation, often the one that classifies a device type
510(k)
premarket notification — the FDA route for a device shown to be as safe and effective as one already on the market; months, no clinical trial as a rule
CKD
chronic kidney disease — long-term loss of kidney function
Class II
FDA device class II — moderate-risk devices, usually cleared by 510(k)
Class III
FDA device class III — the highest-risk devices, usually approved by PMA
CLFS
clinical laboratory fee schedule — the Medicare price list for laboratory tests
CMS
Centers for Medicare & Medicaid Services — the US agency that runs Medicare, and so decides what Medicare pays for
COGS
cost of goods sold — what it costs to make one unit
ctDNA
circulating tumour DNA — fragments of a tumour's DNA found in the blood
De Novo
De Novo classification request — the FDA route for a new, lower-risk device with no comparable product to point at; longer than a 510(k), usually needs clinical data
DEN######
an FDA De Novo decision number — the public record of one device granted a De Novo
DME
durable medical equipment — equipment a patient uses at home, such as a pump or a stimulator, that Medicare pays for under its own rules
DME MAC
durable medical equipment Medicare administrative contractor — one of the four regional contractors that process Medicare's home-equipment claims and write its local coverage rules
DMEPOS
durable medical equipment, prosthetics, orthotics and supplies — the Medicare benefit and fee schedule that home equipment is paid under
E####
a HCPCS code for durable medical equipment — one billing code for a piece of home equipment; the letter E and four digits
EPO
European Patent Office — the European patent office
FDA
US Food and Drug Administration — the US regulator that clears or approves a device before it can be sold
FFS
fee-for-service — the traditional form of Medicare that pays per item or service
FTO
freedom to operate — whether a product can be sold without infringing someone else's live patent
HCPCS
Healthcare Common Procedure Coding System — the US billing codes for equipment, supplies and some services; a code is how a payer recognises what to pay for
IFU
instructions for use — the labelling that says what a device is for and how to use it
IP
intellectual property — patents and the other rights that let a company stop others copying it
ISO
International Organization for Standardization — the body whose numbered standards devices and laboratories are tested against
IVD
in vitro diagnostic — a test run on a sample taken from the body rather than on the body
K######
an FDA 510(k) clearance number — the public record of one cleared device; the letter K and six digits
L#####
a Medicare local coverage determination number — the public id of one local coverage rule; the letter L and five digits
LCD
local coverage determination — a Medicare contractor's rule, valid in its region, saying when something is covered
MA
Medicare Advantage — Medicare delivered through a private insurer; must cover at least what Medicare covers
MAUDE
Manufacturer and User Facility Device Experience — the FDA's public database of reported device problems
Medicare Advantage
Medicare Advantage — Medicare delivered through a private insurer; must cover at least what Medicare covers
Medicare Part B
Medicare Part B — the part of Medicare that pays for outpatient care and equipment used at home
mmHg
millimetres of mercury — the unit blood pressure, and the suction of a wound pump, are measured in
MRD
molecular residual disease — cancer left behind after treatment, too little to see on a scan, detected through DNA in the blood
MSA
multiple system atrophy — a rare degenerative brain disease that, among other things, breaks blood-pressure control
NCD
national coverage determination — a Medicare rule, valid everywhere in the US, saying whether and when something is covered
NCD ###.#
a Medicare national coverage determination number — the public id of one national coverage rule
NCT########
a ClinicalTrials.gov registration number — the public id of one registered clinical trial
nOH
neurogenic orthostatic hypotension — blood pressure that falls on standing because the nerves that should tighten the blood vessels have failed
OH
orthostatic hypotension — blood pressure that falls on standing
PAF
pure autonomic failure — a rare condition in which only the nerves controlling automatic functions such as blood pressure fail
PD
Parkinson disease — Parkinson disease
PDAC
Pricing, Data Analysis and Coding contractor — the Medicare contractor that decides which billing code a specific product falls under
PMA
premarket approval — the FDA route for the highest-risk devices; years and clinical trials
PMID
PubMed identifier — the public id of one published medical paper
RCT
randomised controlled trial — the kind of clinical study that compares a treatment against an alternative by chance assignment
TAM
total addressable market — how much money the whole market would be worth if every possible buyer bought
USPTO
United States Patent and Trademark Office — the US patent office